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INTRODUCTION 
Our laboratory has been interested in characterizing 
the molecular etiology of Hodgkin's disease. Hodgkin's 
disease is an enigma since its description decades ago in 
that little is known of the origin of the malignant cell, 
the etiology and pathology of the disease, nor about the 
molecular basis of tumorigenic transformation. Because of 
this lack of knowledge, diagnosis of the disease is 
difficult, often leading to inappropriate treatment. A 
better understanding of this disease, particularly at the 
molecular level, would help in the management of Hodgkin's 
disease. 
Recently, several groups showed that the Epstein-Barr 
virus (EBV) genome is in the nucleus of Hodgkin's/Reed-
Sternberg cells, suggesting a direct correlation between 
EBV infection and the tumorigenic transformation of cells 
to the Hodgkin's disease phenotype. Based on these 
observations, I hypothesized that the oncogenic events 
responsible for EBV associated and non-EBV associated 
Hodgkin's disease are mediated by aberrant expression of 
cellular genes which are also aberrantly expressed in EBV 
infected non-Hodgkin's lymphoma. A key EBV encoded gene 
involved in immortalization and potentially in 
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transformation is the Epstein-Barr nuclear antigen 2 (EBNA 
2). My objective therefore was to isolate novel cellular 
genes over-expressed in Hodgkin's-disease cells and which 
are potential targets of EBNA 2 in EBV infected cells. To 
do so, I developed a differential screening procedure to 
isolate such genes in an EBV negative Hodgkin's disease 
cDNA library that hybridize to probes from EBNA 2 
expressing African Burkitt's lymphoma cell line, but which 
do not hybridize with probes from an African Burkitt•s 
lymphoma cell line lacking EBNA 2. 
The result of the screening procedure was the 
isolation of a novel cDNA that we named ELAG (Early 
Lymphoid Activation Gene) based on its transient 
expression during activation of peripheral blood 
mononuclear cells (PBMC) with either phytohemagglutinin 
(PHA) or anti-CD3 monoclonal antibody. Analysis of the 
open reading frame suggests that ELAG may encode a nuclear 
phosphoprotein. I hypothesize that ELAG expression may be 
required for the activation of other genes involved in the 
T cell activation cascade. Because ELAG is tightly 
regulated during the activation and proliferation of 
normal lymphoid cells, it would therefore be an ideal 
candidate gene as a novel oncogene that when over-
expressed may provide aberrant signals that are involved 
in tumorigenic transformation. 
Further investigation of ELAG may provide a better 
understanding of the poorly understood yet highly 
intricate regulation of T cell activation during the 
immune response. Additionally, characterization of the 
normal function of ELAG may provide clues about its 
potential role in tumorigenesis. 
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REVIEW OF RELATED LITERATURE 
I. overview of the disease 
Hodgkin's disease was originally characterized in 
1832 by Thomas Hodgkin's in a paper describing the 
clinical histories and postmortem observation of six 
people with enlarged lymphatic glands (Kaplan, 1980). 
Seventy years later Carl Sternberg and Dorothy Reed 
described the characteristic giant multinucleate cells in 
the diseased region of a Hodgkin's disease tumor. This 
malignant cell of Hodgkin's disease is now known as the 
Reed-Sternberg cell. In addition to the Reed-Sternberg 
cell, a mononuclear variant cell is often identified in 
diseased tissue. The distinction between the mono- and 
multi-nuclear cells is unclear and potentially represent 
the same cell type. Therefore, for the clarity in this 
thesis the malignant cell in Hodgkin's disease tissue will 
be referred to as the Hodgkin's/Reed-Sternberg cell (H/RS) 
which refers to both the mono- and multinuclear cell. 
The definition of Hodgkin's disease as a malignancy 
has been controversial in the past because of the low 
abundance of H/RS cells in the tumor (Kaplan, 1980). The 
H/RS cell often comprises less than 1% of the tumor mass 
4 
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while most of the tumor is comprised of non-neoplastic 
infiltrate (Anastasi et al., 1987; Cossman et al., 1988). 
The malignant nature of Hodgkin's disease was questionable 
because of its pathology. Close analysis of the H/RS 
cells reveals characteristics similar to other tumor 
cells. H/RS cells in diseased lymph nodes are often 
characterized by aneuploidy and clonality (Thangavelu and 
Le Beau, 1989). Additionally, tumors produced by 
heterotransplantation into nude mice strongly resemble 
Hodgkin's disease, a finding which supports the contention 
that Hodgkin's disease is a malignancy (Diehl et al., 
1982; Schaadt et al., 1979). 
Hodgkin's disease is characterized by a defect in 
cellular immunity whereas humoral immunity remains 
unimpaired (Twomey and Rice, 1980; Bjorkolm et al., 1982; 
Fisher, 1982). Patients with Hodgkin's disease have an 
increased incidence of infection with opportunistic 
pathogens including fungi, viruses, and tuberculosis 
(Slivnick et al., 1989). The H/RS cell is in an activated 
state and secretes lymphokines which affect the immune 
system (Borowitz et al., 1982; Maggi et al., 1988; Poppema 
et al., 1982). Patients in advanced stages of Hodgkin's 
disease die of severe immunosuppression. 
The etiology of Hodgkin's disease is poorly 
understood. Investigations by MacMahon showed a bimodal 
age-specific incidence curve (MacMahon, 1957). Analysis 
6 
of the incidence curve shows a specific incidence peak for 
individuals between the ages of 15 to 45. Other 
investigators suggested that Hodgkin's disease in younger 
patients tends to be an inflammatory disease whereas 
Hodgkin's disease in older patients is more similar to a 
neoplasm. MacMahon therefore suggested that Hodgkin's 
disease may not be a single entity but a syndrome 
comprising at least two entities with different 
etiologies. 
My goal was to investigate the molecular etiology of 
Hodgkin's disease. The impetus for the initiation of this 
project stemmed from the lack of knowledge regarding the 
cellular and molecular basis of Hodgkin's disease. 
Because of this lack of information, diagnosis and 
treatment are often difficult. On the other hand, 
Hodgkin's disease is curable when diagnosed early enough 
and chemotherapy is initiated. Therefore, a better 
understanding of the molecular etiology might help us 
understand how various drug therapies work and how to 
improve them. The discussion in this Literature Review 
section addresses the current status of information 
regarding Hodgkin's disease. Additionally, I have 
reviewed the recent literature on Epstein-Barr virus (EBV) 
and its association with the Hodgkin's disease phenotype 
that led to the initiation of this project. 
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II. Characterizing and defining the Hodgkin's-disease cell 
Hodgkin's disease remains an enigma in that it is 
very poorly characterized. Analysis of the histological 
type and the cellular origin of the Hodgkin's-disease cell 
has demonstrated that Hodgkin's disease is more 
characteristic of a diverse range of cancers than of a 
single disease entity. 
A. Histopathology reveals a diversity of transformed cells 
in Hodgkin's disease tissue 
Hodgkin's disease is a diverse disease, and 
therefore, pathologists have attempted to morphologically 
and prognostically categorize the heterogeneous nature of 
Hodgkin's disease. Four histopathological classifications 
have been proposed to categorize Hodgkin's disease tumors; 
nodular sclerosis, mixed cellularity, lymphocytic 
predominance, and lymphocytic depleted (Lukes, 1971; Lukes 
and Butler, 1966a; Lukes et al., 1966b). The histologic 
subtype is not an independent prognostic factor if the 
disease is treated appropriately. 
Unequivocal diagnosis of Hodgkin's disease can only 
be made by microscopic examination of one or more tissue 
specimens (Anastasi et al., 1989). However, it is often 
difficult to make an accurate characterization and 
diagnosis of the disease due to many factors specific to 
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Hodgkin's disease. First, as described earlier, the 
malignant cell often comprises a very low percentage of 
the actual tumor mass (Anastasi et al., 1987; Cassman et 
al., 1988). Second, there are different types of H/RS 
cells. Malignant cells in a Hodgkin's disease tumor are 
either mononuclear cells or contain multiple nuclei. 
Additionally, cells similar to the H/RS cells are often 
found associated with other pathological events such as 
inflammatory lymphadenopathy and infectious mononucleosis. 
Therefore, it is difficult to diagnose Hodgkin's disease 
specifically based on the observation of a cell that looks 
like a H/RS cell in a biopsy (Anastasi et al., 1989). 
B. Origin of the Hodgkin's/Reed-Sternberg cell 
The precursor cell of Hodgkin's disease is unknown. 
Investigators have attempted to characterize the cellular 
origin of the H/RS cell in lymphoid tissue and in cell 
culture lines by utilizing immunohistochemical staining 
and morphologic analysis. Conflicting reports describe 
the H/RS cell as a B lymphocyte (Taylor, 1974; Boecker et 
al., 1975; Linch et al., 1985; Pinkus and Said, 1988), T 
lymphocyte (Andreesen et al., 1984; Kadin, 1985), 
monocyte-macrophage (Strauchen, 1984; Kadin, 1993; 
Andreesen et al., 1989; Foon and Todd, 1986; Payne et al., 
1982), or as originating from an interdigitating reticulum 
cell (Hansmann and Kaiserling, 1982; Kadin, 1982). 
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Morphologic analysis of Hodgkin's disease lymph nodes 
revealed ultrastructural similarities between H/RS cells 
and either lymphocytes or interdigitating reticulum cells. 
Both interdigitating reticulum cells and H/RS cells 
function as antigen presenting cells, and lack 
differentiation antigens characteristic of monocytes, and 
pre-B or pre-T cells (Kadin, 1982; Stein et al., 1982). 
However, interdigitating reticulum cells fail to stain 
with monoclonal antibodies specific for surface markers of 
H/RS cells, including HeFi-1 or Ki-1 (Schwarrting et al., 
1987; Stein et al., 1982). Additionally, H/RS cells fail 
to stain with monoclonal antibodies which specifically 
bind reticulum cells including OKT6 (Stein et al., 1982; 
Stein et al., 1983). 
Investigations demonstrating that H/RS cells 
positively stain for alpha-1 antitrypsin, alpha-1 
antichymotrypsin, acid phosphatase, and Fe receptors led 
some investigators to suggest that H/RS cells originate 
from a monocyte/macrophage cell lineage (Strauchen, 1984; 
Kadin, 1993; Andreesen et al., 1989; Foon and Todd, 1986; 
Payne et al., 1982). However, alpha-1 antitrypsin is also 
expressed in activated lymphoblasts (Payne et al., 1982; 
Jones et al., 1986). Further, H/RS cells do not react 
with monocyte specific antibodies and lack phagocytic 
properties characteristic of macrophages (Stein et al., 
1982; Dorreen et al., 1984; Stein et al., 1986). 
Conversely, monocytes and macrophages do not react with 
the Ki-1 monoclonal antibody (Jones et al., 1986; 
Schwarrting et al., 1987; Stein et al., 1983). 
10 
Many recent investigations support the notion that 
H/RS cells originate from lymphocytes. Activated T cells 
react with the monoclonal antibody anti-Leu-M 1, which 
typically stains H/RS cells (Schwarrting et al., 1987; 
Timens et al., 1986). The presence of IL-2 (interleukin 
2) receptors further support the contention that H/RS 
cells are of lymphoid origin (Schwarrting et al., 1987). 
Additionally, lymph node specimens have revealed the 
presence of H/RS cells that react with pan B monoclonal 
antibodies (Pinkus and Said, 1985; Timens et al., 1986). 
An analysis of H/RS cells in tissue culture indicates 
that there may be spectrum of cell types involved in the 
development of Hodgkin's disease. One study showed that 
one Hodgkin's-disease cell line, L428 is comprised of 
three morphologically distinct cells; larger multinucleate 
Reed-Sternberg cells and medium size mono- or bi-nucleated 
cells (Schaadt et al., 1979; Diehl et al., 1981). It is 
likely that the different subtypes of Hodgkin's disease 
arise from different progenitor cells types (Slivnick et 
al., 1989). Efforts to characterize the lineage of the 
H/RS cell will continue with the hope of improving the 
efficiency of diagnosis. 
11 
Several cellular genes are over-expressed in 
association with Hodgkin's disease. These genes include 
CD30, CD15, CD74, CDw70 and interleukin-6 (IL-6) and IL-9. 
However, these genes are expressed in a wide range of 
tumor cell types and therefore there specific role in the 
development of Hodgkin's disease is unclear. 
Additionally, the cell surface markers are not 
consistently expressed on all H/RS cells. One study 
showed that CD30 is expressed in H/RS cells of 
approximately 70% of the Hodgkin's disease nodes tested 
and CD15 was detected on only 65% of the diseased nodes 
tested (Chu et al., 1992). To date, there is no consensus 
immunophenotype of the H/RS cell. 
c. Molecular basis of Hodgkin's disease 
1. Cytogenetic abnormalities 
Efforts to characterize the origin of the H/RS cell 
have led to the identification of cytogenetic 
abnormalities that are potentially specific for Hodgkin's 
disease. To better understand the molecular biology of 
Hodgkin's disease and to provide data about the oncogenic 
events, several investigators have tried to characterize 
molecular anomalies that correlate with the transformed 
phenotype. Unique cytogenetic abnormalities that 
demonstrate a high correlation with Hodgkin's disease or 
Hodgkin's disease subtype have not been identified 
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(Thangavelu and Le Beau, 1989). This is in sharp contrast 
to other hematopoietic tumors such as Burkitt•s lymphoma 
and chronic myelogenous leukemia which demonstrate 
distinct chromosomal alterations which are considered as 
molecular hallmarks of these disease types. Burkitt•s 
lymphoma is characterized by a translocation of the c-myc 
proto-oncogene with human immunoglobulin heavy chain 
[t(8;14], kappa light chain (t(8;2], or the lambda light 
chain genes (t(8;22] (Della-Favera et al., 1982; Taub et 
al., 1982; Della-Favera et al., 1983; Adams et al., 1983; 
Hollis et al., 1984; Davis et al., 1984; Pelicci et al., 
1986). The translocation results in the constitutive 
expression of the c-myc gene (Croce and Nowell, 1985; 
Croce, 1987; Bishop, 1987). CML is characterized by the 
observation of the Philadelphia chromosome in which the c-
abl gene found on chromosome 9 is fused with the coding 
sequences of the bcr gene (Rowley, 1973; de Klein et al., 
1982). The resulting fusion gene is translated as a 
chimeric protein with enhanced activity (Konopka and 
Witte, 1985; Westbrook, 1988). However, the number of 
cases studied may be too few to make any conclusions. 
Further study of the H/RS cell may provide answers that 
will eventually allow for the use of cytogenetic 
aberrations as a prognostic marker, such as those 
identified with non-Hodgkin's lymphomas. 
13 
Anueploidy, or altered diploid number, is a common 
characteristic of the H/RS cell (Fleishmann et al., 1976; 
Hansmann et al., 1986; Hess et al., 1986; Kristoffersson 
et al., 1987; Reeves and Pickup, 1980; Seif and Spriggs, 
1967; Slavutsky et al., 1985). Increased copy number of 
chromosome 5 was characterized in over 25% of cases 
studied (Thangavelu and Le Beau, 1989). Additionally, a 
gain of chromosomes 1,2,9,ll,12,16,18,20 and 21 occurred 
in at least 10% of the cases. The loss of chromosomes 10, 
13, 17, 21 and 22 were observed in nearly 10% of all 
cases. Loss of chromosome 3 was never observed. 
A review of the same cases described above showed 
that structural alterations were identified which involved 
chromosome arms lp (25%), lq (25%), as well as chromosome 
arms 2q (16%), 6q (21%), llp (12%), llq(12%), and 14q 
(12%). Aberrant chromosomal banding patterns were 
frequently found at positions lp21, 5pl5, llpl3, 14q32 and 
18pll. As discussed above, aberrations of chromosome band 
14q32 are frequently found in B cell neoplasms (over 70% 
of the cases), suggesting a B cell origin for these 
particular cases of Hodgkin's disease. 
In the study described here, I characterize a novel 
gene from the Hodgkin's-disease cell line L428, which 
might be deregulated in this cell type. An understanding 
of the karyotype of the L428 cell may eventually be 
important in the interpretation of the results of the 
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study described here because genes over-expressed in these 
cells could potentially be deregulated due to a 
translocation event. The specific chromosomal aberrations 
identified in the L428 were found at positions 2q33, 7q22-
36, llq21/23, 14q32, and 21q21-22. As discussed above, 
aberrations at position 7q35 are found at high frequencies 
in T cell tumors while aberrations at position 14q32 are 
frequently identified with B cell lymphomas. 
2. Oncogenes in Hodgkin's disease 
It is suspected that activation of proto-oncogenes 
may be involved in the development of Hodgkin's disease. 
Perhaps a translocation, as discussed above, may be 
responsible for activating a proto-oncogene. Other 
potential mechanisms that may be involved include point 
mutations (Bishop, 1987), over expression due to gene 
amplification (Bishop, 1987; Marcu et al., 1992), or 
inactivation of a tumor suppressor gene such as the 
retinoblastoma gene (Rb) (Levine, 1993). 
The difficulty in characterizing gene expression in 
the H/RS cell of a diseased lymph node stems from the low 
proportion of tumor cells to normal tissue. Therefore, 
several groups analyzed H/RS cell lines to determine if 
any proto-oncogenes are consistently activated. 
Jucker et al. analyze the expression of 20 proto-
oncogenes in four H/RS cell lines (L428, L540, co, and 
DEV) compared to their expression in normal hematopoietic 
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cell (Jucker et al., 1990). They found that c-myc, p53, 
c-jun, pim-1, p56-lck, c-syn, c-raf and N-ras were each 
expressed in at least three of the four cell lines tested. 
Additionally, they observed that N-myc and p56-1ck were 
only expressed in the CO cell line which also expresses T 
cell receptor genes. 
Specifically, the analysis of oncogene expression in 
the L428 Hodgkin's-disease cell line showed that c-myc, c-
jun, c-syn, c-myb, c-met, pim-1, c-raf and p53 demonstrate 
normal levels of expression (Jucker et al., 1990). Other 
proto-oncogenes tested including N-myc, L-myc, c-fos, c-
src, c-fgr, p56-lck, c-mos were not detected. 
Additionally, no mutations were identified in any of these 
genes. However, aberrant transcripts from the c-fes gene 
were identified. No point mutations were found in the Ki-
ras, H-ras or the N-ras gene. 
More recent studies have used in situ hybridization 
and immunohistochemical techniques to directly analyze 
gene expression in the H/RS cells in diseased tissue. One 
study has shown that p53 is over-expressed in the H/RS 
cell in 32% of the cases analyzed (Niedobitek et al., 
1993). Their investigation did not reveal any specific 
mutations in the gene but instead suggest that over-
expression of this tumor suppressor gene may be an 
indicator of altered wild-type p53 function. Two 
additional studies suggest a role of activated bcl-2 (Jiwa 
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et al., 1993; Reid et al., 1993). One study showed that 
the both c-myc and bcl-2 are expressed in the H/RS cell in 
72% of samples tested and suggested that these two 
oncogenes may act in concert to affect the pathogenesis of 
Hodgkin's disease (Jiwa et al., 1993). 
III. Epstein-Barr virus (EBV) and Hodgkin's disease 
Since the original discovery of the virus by Epstein, 
Barr and Achong (Epstein et al., 1964; Epstein and Barr, 
1964; 1986), the Epstein-Barr virus (EBV) was found to 
cause infectious mononucleosis and has become associated 
with the development of Burkitt•s lymphoma (Epstein et 
al., 1964; Epstein and Barr, 1964; 1986), nasopharyngeal 
carcinoma (Hirayama and Ito, 1981; Fahraeus et al., 1988; 
Chan et al., 1989; Tomei et al., 1987; Young et al., 1988) 
and lymphoproliferative diseases induced in 
immunosuppressed patients (Cen et al., 1993; Seiden and 
Sklar, 1993; Purtilo et al., 1992). It has long been 
suggested that the Epstein-Barr virus (EBV) may also be 
involved in the development of Hodgkin's disease. 
Epidemiological studies supported this contention by 
identifying a higher incidence of Hodgkin's disease among 
people who had been afflicted with infectious 
mononucleosis (Kaplan, 1980). However, the association of 
EBV and Hodgkin's disease, without direct evidence, 
remained questionable. 
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Studies by Sklar and colleagues showed in southern 
blot analysis of biopsy tissue from Hodgkin's disease 
patients that the EBV genome is harbored in the tumor mass 
(Weiss et al., 1987). However, because the H/RS cells 
generally makes up less than 1% of the tumor mass, these 
studies did not conclusively demonstrate the presence of 
EBV in the H/RS cells. These findings could have been the 
result of an EBV infected B cell population in the lymph 
node. 
A later study by this same group utilized in situ 
hybridization to directly demonstrate that the EBV genome 
was harbored in the H/RS cell of disease lymph nodes in 
20% of the Hodgkin's-disease patients tested 
(Anagnostopoulos et al., 1989; Weiss et al., 1989). These 
findings supported the contention that EBV may be involved 
in the development of Hodgkin's disease. Similar studies 
by other investigators showed that the EBV genome is 
harbored in the H/RS cell of potentially 60% of the 
patients tested (Staal et al., 1989; Libetta et al., 
1990). One study which utilized PCR to detect EBV claimed 
that as many as 78% of diseased nodes contained the EBV 
genome (Herbst et al., 1990). However these results are 
dubious in that the sensitivity of PCR may allow for the 
detection of EBV in a small population of contaminating 
non-H/RS cells. 
18 
I was interested in the association between EBV 
infection and the development of Hodgkin's disease and 
hypothesized that the oncogenic events responsible for 
Hodgkin's disease, both EBV associated and EBV negative 
independent Hodgkin's disease, are mediated by aberrant 
expression of cellular genes which are also aberrantly 
expressed in EBV infected non-Hodgkin's lymphoma. My 
objective was to develop a screening procedure to isolate 
cellular genes that may be affected by the presence of EBV 
and that contribute to the transformed phenotype of 
Hodgkin's disease. In order to describe the screening 
method that I utilized, it is necessary to review the 
molecular biology of the Epstein-Barr virus and what is 
known about the role of EBV in tumorigenic transformation. 
IV. Molecular basis for EBV immortalization and 
transformation 
A. The EBV genome 
The Epstein-Barr virus was originally identified and 
isolated from African Burkitt's lymphoma tumors (Epstein 
et al., 1964; Epstein and Barr, 1964; 1986). The EBV 
genome of the virus is a double stranded DNA molecule of 
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approximately 173 kb (Baer et al., 1984). It has been 
cloned as a set of overlapping fragments of the 
restriction enzymes EcoR I and BamH I and regions of the 
genome are generally ref erred to by the name of the 
corresponding BamH I fragment. The EBV genome potentially 
encodes over 100 genes, however, the virus remains in a 
latent state while expressing only a few EBV encoded 
genes. These include the following: the Epstein-Barr 
nuclear antigens [EBNA] 1, 2a, 2b, 3a, 3b, Jc, 4, 5, and 
6; the leader peptide, LP; the latent membrane proteins 
[LMP] 1, 2a and 2b; and the EBV encoded RNAs EBER 1 and 
EBER 2. One gene recently described that is expressed 
during the lytic phase is the EBV replication activator 
ZEBRA (Baumann et al., 1993). 
B. Expression of EBV encoded genes during latent infection 
1. LCL phenotype 
The in vitro EBV-infected B lymphocytes are 
immortalized into lymphoblastoid cell lines (LCL) which 
have gained the ability to proliferate in culture 
indefinitely (Baichwal and Sugden, 1988; Rogers et al., 
1992; Middleton et al., 1991; Klein, 1989). These cells 
usually do not produce virus particles. Instead the virus 
remains in a latent state with only a small number of EBV 
encoded genes being expressed. Much of our understanding 
about the pattern of EBV gene expression and the function 
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of EBV encoded genes has come from studies of EBV infected 
LCLs. 
EBNA 1 is required for replication of the virus 
(Yates et al., 1985; Lupton and Levine, 1985). This is 
the only viral protein consistently expressed in EBV 
immortalized cells. This protein specifically binds to 
sequences at the origin of replication, to facilitate 
replication (Lupton and Levine, 1985). EBNA 1 has also 
been shown to transactivate viral transcription from the 
BamH I K-promoter of the EBV genome (Sugden and Warren, 
1989) . 
The role of EBNA 3a, 3b, Jc, 4, 5 and 6 are poorly 
understood (Rogers et al., 1992). However EBNA 3 proteins 
have an affinity for single stranded DNA (ssDNA) while 
EBNA 4 has an affinity for both single stranded DNA 
(ssDNA) and double stranded DNA (dsDNA) (Rowe et al., 
1989; Rogers et al., 1992). The function of the non-
coding EBERs is unclear, but the presence of EBER is 
recognizes as the most consistent indicator of latent EBV 
infection (Raab-Traub and Flynn, 1986). Additionally the 
roles of the EBV encoded products in the development of 
the transformed phenotype has not been distinguished. 
Other latent proteins include EBNA 2, LMP, and the 
BamH I A reading frame encoded proteins. Because of the 
association between these proteins and the ability of EBV 
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to immortalize and transform cells, these proteins will be 
discussed in a section addressing this important aspect. 
The ZEBRA protein is translated from transcripts from 
the EBV BamH I Z-fragment (BZLF 1). Expression of this 
protein alone is sufficient to activate the lytic cycle of 
EBV infection (Baumann et al., 1993). ZEBRA shares 
homology with AP-1 transcriptional factors including Fos, 
Fra-1, Jun, and Jun-B (Carey et al., 1992; Sato et al., 
1992). This EBV encoded protein is able to bind to the 
AP-1 site of the c-fos promoter and induce expression of 
c-fos (Carey et al., 1992). This protein binds the 
canonical TRE/AP-1 site and therefore is potentially able 
to transactivated several cellular genes. 
2. Burkitt•s lymphoma 
EBV was first discovered in a cell line derived from 
Burkitt•s lymphoma tissue (Epstein et al., 1964; Epstein 
and Barr, 1964; 1986). The pattern of latency observed in 
these cells in greatly restricted in that only EBNA 1 is 
expressed (Rowe et al., 1987; Gregory et al., 1990) when 
the cell lines are first established in culture. 
Continued passage of these cells results in the 
progression from this restricted pattern of latency to a 
phenotype that more closely resembles an LCL. When first 
in culture, Burkitt•s lymphoma cell lines are classified 
as type 1 (Burkitt•s lymphoma type) with a restricted 
latency. Type 2 cells have an intermediate latency 
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pattern of EBV gene expression and type 3 develop an LCL-
like phenotype (Altiok et al., 1992; Rowe et al., 1987; 
Gregory et al., 1990). Type 3 Burkitt's lymphoma cell 
express most EBV latent proteins as well as cellular 
antigens characteristic of an LCL. 
3. Nasopharyngeal carcinoma and Hodgkin's disease 
A third pattern of latency is exhibited in 
nasopharyngeal carcinoma cells. These cells express EBNA 
1, LMP and transcripts originating from the BamH I open 
reading frame (Gilligan et al., 1990). Recent studies 
have shown by in situ hybridization that EBV infected H/RS 
cells express the same EBV encoded genes (Deacon et al., 
1993). The role of these transcripts and the proteins 
that they potentially encode is not known. 
c. The role of EBV encoded genes in immortalization and 
transformation 
Although the ability of EBV to tumorigenically 
transform human cells is likely due to the coordinate 
activity of the latent proteins described above, the 
direct immortalization and transformation is likely 
triggered by two EBV encoded proteins; the Epstein-Barr 
virus nuclear antigen 2 (EBNA 2) and the latent membrane 
protein family (LMP 1, LMP 2a and LMP 2b). The recently 
identified transcripts originating from the BamH I A-
fragment may also be involved in transformation. 
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1. BamH I A-open reading frame 
A family of transcripts expressed in NPC cells, 
originating from the BamH I A-region of the EBV genome 
have recently been characterized (Gilligan et al., 1990). 
The proteins translated in vitro from these transcripts, 
32-kDa, 26-kDa, 17-kDa, 15-kDa, and 11-kDa, are poorly 
characterized and their functions are unknown. Similar 
transcripts have been identified in the H/RS cells 
infected with EBV (Deacon et al., 1993). 
2. LMP proteins 
The LMP is transcribed as a 2.6-kb RNA which is 
spliced as a 2.4-kb mRNA containing a 1.3-kb open reading 
frame. The translated protein has six hydrophobic 
transmembrane domains. The protein is translated as a 58-
kDa protein. Analysis shows that the LMP proteins form 
patches on the cell surface indicating that it may be part 
of a complex of proteins that may be necessary for 
immortalization. 
LMP 1 has been characterized as a true oncogene 
(Moorthy and Thorley-Lawson, 1992; Niedobitek et al., 
1992; Wang et al., 1990). Rodent fibroblast transfected 
with this gene loose anchorage dependence acquire a 
transformed phenotype (Wang et al., 1985; Wang et al., 
1988; Wang et al., 1985). LMP 1 has been shown to act 
with EBNA 2 to cooperatively induce expression of cellular 
genes (Wang et al., 1990). Despite the clear results of 
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tissue culture studies, the biochemical function of LMP in 
human cells and the development of human tumors is 
unclear. LMP 1 expression will induce the expression of 
bcl-2 resulting in the protecting the cell from apoptosis 
(Henderson et al., 1991). 
LMP 2A and 2B have recently been identified 
(Longnecker and Kieff, 1990). These two proteins are 
translated from alternatively spliced transcripts which 
are translated as nearly identical proteins except that 
the LMP 2A protein contains an additional 119 amino acids 
at its amino terminus (Peng and Lundgren, 1993). LMP 2A 
has been found to co-localize to the cellular membrane 
with LMP 1 (Longnecker and Kieff, 1990). The importance 
of this association is unclear. The association of LMP 2B 
with LMP 1 is only speculative at this time. The function 
of these two proteins are unknown. 
3. EBNA 2 
EBNA exists as two antigenically different proteins, 
EBNA 2A and EBNA 2B, which share 50% amino acid homology 
(Dambaugh et al., 1984; Addinger et al., 1985). The 
majority of EBV strains characterized to date encode EBNA 
2A while EBNA 2B appears to be encoded by an EBV strain 
which is restricted to areas of equatorial Africa (Rowe et 
al., 1989). Because EBNA 2A is the better characterized 
protein, and in much of the literature EBNA 2 is 
synonymous with EBNA 2A unless otherwise mentioned, only 
EBNA 2A will be addressed. 
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EBNA 2 is a key determinant of lymphocyte 
transformation (Cohen et al., 1989; Cohen et al., 1992). 
This protein shares homology with the three viral 
oncogenes; adenovirus ElA, human papilloma virus-16 E7 and 
SV40 large T antigen (Harada and Yanagi, 1991). EBNA 2 is 
a transactivator of viral genes such as LMP 1 (Reisman and 
Sugden, 1986; Tsang et al., 1991; Tsang et al., 1991; Wang 
et al., 1991b; Abbot et al., 1990) and cellular genes 
(Cohen and Kieff, 1991; Rogers et al., 1992). Infection 
of B cells with EBV results in the expression of CD23 
(Wang et al., 1990; Wang et al., 1987; Wang et al., 
1991a), CD21 (Calender et al., 1987), CD30 (Calender et 
al., 1987), Bac-1 (Calender et al., 1987), and c-fgr 
(Knutson, 1990). Cells transfected with EBNA 2 
demonstrate obvious changes observed during EBV infection 
including increased growth in clumps. 
The role of EBNA 2 in immortalization was clearly 
demonstrated in studies comparing the viral strains of two 
African Burkitt•s lymphoma cell lines; Jiyoye and P3HR-1. 
The Jiyoye cell line was developed from the tumor cells of 
an African Burkitt's lymphoma. The cell is infected with 
a strain of EBV that encodes EBNA 2B (Hinuma and Grace, 
1967). Virus isolated from tissue culture supernatants of 
Jiyoye cells can infect peripheral blood B lymphocytes and 
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result in the development of an immortalized cell line. 
The P3HR-1 cell line is a tissue culture derivative of the 
Jiyoye cell line (Hinuma and Grace, 1967). The P3HR-1 
viral strain, which lacks the gene encoding EBNA 2 due to 
a spontaneous deletion, has lost the ability to 
immortalize cells in culture (Jeang and Hayward, 1983; 
Bornkamm et al., 1982). 
It is hypothesized that EBNA 2 immortalizes cells by 
inducing aberrant expression of cellular genes like CD30 
and CD23 (Cordier et al., 1990; Calender et al., 1987; 
Wang et al., 1987). Furthermore, it is likely that these 
cellular genes required for immortalization are expressed 
in Jiyoye cell line but that the P3HR-1 cells no longer 
expresses these cellular genes (Murray et al., 1988). 
Based on this information, I developed a differential 
screening method that would target cellular genes, like 
CD23 and CD30 or any normal gene that is a target of EBNA 
2 and that is expressed in Hodgkin's disease. 
MATERIALS AND METHODS 
I. Isolation of a novel cDNA clone 
A. Analysis of transformed cell lines; development of the 
differential screening protocol 
All tissue culture cell lines were maintained in RPMI 
1640 (Hazelton, Lenexa, KA) supplemented with 10% fetal 
calf serum (Hazelton, Lenexa, KA), 50 U/ml penicillin 
(Sigma, St. Louis, MO), 50 µg/ml streptomycin (Sigma, St. 
Louis, MO) and 2 mM L-Glutamine (Sigma, St. Louis, MO). 
The cells were stored in a humidified chamber at 37oc with 
5% C02. The Hodgkin's-disease cell line L428 was 
originally described by Schaadt and collegues (Schaadt et 
al. 1979; Schaadt et al., 1980), and was obtained from Dr. 
R. Fisher (Department of Hematology/Oncology, Loyola 
University - Chicago, Maywood, IL). The African Burkitt's 
lymphoma cell lines Jiyoye and PJHR-1 were provided by Dr. 
B. Sugden (Department of Oncology, University of Wisconsin 
- Madison, Madison, WI). 
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B. Differential screening of the Hodgkin's-disease cDNA 
library 
1. L428 cDNA library 
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Highly purified poly A+ RNA was isolated from L428 
cells and a cDNA library was prepared by Stratagene (La 
Jolla, CA). The library was packaged into the Lambda 
ZAP™ vector. The poly A+ RNA used to synthesize the cDNA 
library was prepared as described in section IV.C.1 of the 
Materials and Methods. 
2. cDNA probes 
In order to achieve the sensitivity required for 
detection of genes expressed in low abundance, it was 
necessary to produce the cDNA molecules that have 
incorporated a high level of radiolabeled nucleotide. The 
procedure that I have developed to do so was a combined 
protocol derived from methods previously described 
(Gerard, 1988) and from personal communications with 
several laboratories that are currently using this 
procedure. Whole cell poly A+ RNA was isolated from the 
Jiyoye and P3HR-1 cell lines as described in the sections 
below. The cDNA was synthesized from the RNA according to 
the following protocol. Twenty micrograms of poly A+ RNA 
was denatured in 20 µl of water at 65oc for 10 minutes. 
The denatured RNA was then added to a tube containing 60 
µl of the following solution: 50 mM Tris (pH 8.3), 40 mM 
potassium chloride, 8 mM magnesium chloride, 5 mM OTT 
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(dithiothreitol), 500 µM of unlabeled dCTP, dGTP and dTTP, 
10 µM of unlabeled dATP (Pharmacia, Piscataway, NJ) 1 µM 
of [a32p]-dATP (ICN, Irvine, CA; specific activity 
greater than 3000 Ci/mmol), and 120 units of RNasin 
(Promega, Madison, WI). The reduced molarity of the 
unlabeled dATP is critical for the high level of 
incorporation of the radiolabeled dATP in the synthesized 
cDNA molecules. Four thousand (4000) units of Mo-MuLV 
derived reverse transcriptase (BRL, Bethesda, MD) were 
added and the reaction was incubated at 42°C for three 
hours. The RNA template was hydrolyzed by the addition of 
120 µl of a 150 mM solution of NaOH (to a final pH = 10.5) 
and incubating at 10°c for 20 minutes. The solution was 
then neutralized by the addition of 20 µl of 1 N HCl, 
extracted twice with phenol, twice with phenol/chloroform, 
twice with chloroform, and once with ether. The cDNA was 
then precipitated with ethanol using 0.2 M NaCl and two 
volumes of ethanol at -a5oc for at least one hour and 
pelleted by centrifugation. The dried pellet was 
resuspended in 30 µl of TE (pH 7.7), and purified from 
non-incorporated nucleotides by G-50 Sephadex column 
chromatography. Determination of peak fractions 
containing the cDNA was done with a hand held Geiger 
counter. I typically obtain probes with a specific 
activity of greater than 109 cpm/µg. 
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3. Library screening 
The cDNA probes prepared above were used to screen 
the L428 cDNA library packaged in Lambda Zap™ 
(Stratagene, La Jolla, CA). standard screening procedures 
were utilized (Sambrook et al., 1989). Screening 
protocols were designed so that a 150 mM diameter petri 
dish would contain 2000 pfu when screening with cDNA 
probes synthesized from both Jiyoye and P3HR-1 cell mRNA. 
A 400 µl sample of a suspension of BB4 bacteria, grown to 
an O.D.6oo = 0.5, were incubated with 600 µl of the Lambda 
Zap™ library diluted in SM (50 mM Tris HCl [pH= 7.5], 
100 mM NaCl, 10 mM Mgso4 , 0.01% gelatin) buffer to yield 
the pfu as described above. The mixture was incubated at 
37°c for 15 minutes. To this mixture was then added 8 ml 
of 0.7% top agarose made in NZYM (10 g/l casein amino 
acids, 5 g/yeast extract, 10 g/l NaCl, 10 mM MgS04) media 
that was previously sterilized and cooled to a temperature 
of 40-45oc. The tube containing the suspension was 
quickly inverted several times to evenly suspend the 
bacteria and poured directly onto a 1.5% NZYM agar plate. 
Once solidified, the plates were incubated at 37°c until 
the desired size of plaques developed (approximately five 
to seven hours), and chilled at 4oc for one hour to harden 
the top agarose. Duplicate nitrocellulose filters were 
laid on the plates. The first filter was left on the 
plate for two minutes, and the second filter was left on 
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the plate for seven minutes. Orientation of the filters 
was achieved by piercing through both nitrocellulose and 
agarose with an 18 gauge needle in an asymmetric pattern. 
Filters were then incubated in a solution of 1.5 M NaCl 
and 0.5 M NaOH for two minutes to denature the DNA, 
neutralized by incubating in a solution of 1.5 M NaCl and 
0.5 M Tris (pH 8.0) for five minutes, then washed in 0.2 M 
Tris (pH 7.5) containing 2X SSC (0.3 M NaCl and 0.03 M 
sodium citrate) for 30 seconds and dried completely. They 
were then baked under vacuum at 85°c for two hours. The 
filters were incubated in prehybridization buffer 
containing 50% formamide, lX PIPES buffer, 0.5% sos, and 
0.5 mg/ml denatured salmon sperm DNA in sealed plastic 
bags for at least one hour at 42°c. The buffer was then 
removed and replaced with 5 ml of fresh prehybridization 
buff er and the radiolabeled cDNA probes were added to a 
final concentration of 107 cpm/ml. The filters were 
hybridized with the probe at 42oc for 12-24 hours with 
shaking and then washed according to the following 
procedure that I have empirically developed to obtain 
maximum signal to noise ratio: twice in buffer containing 
2X SSC, 0.1% sos at room temperature for 10 minutes, twice 
in the same buffer at 65°c for 20 minutes, and once in 
buffer containing O.lX SSC, 0.1% sos at 65°c for 10 
minutes. Washed filters were then exposed to X-ray film 
with intensifying screens at -8soc. Hybridizing plaques 
were isolated and rescreened to purify specific clones. 
c. Characterization of cDNA clones 
1. Rescue of cDNA clones 
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The cDNA inserts from the lambda Zap clones were 
rescued into the plasmid pBluescript™ following the 
procedure recommended by Stratagene. Bacteria infected 
with a lambda clone were incubated with the helper phage 
R408 provided by Stratagene during which time the cDNA 
insert was automatically excised and rescued into an EcoR 
I restriction site in pBluescript. The rescued insert in 
pBluescript was transformed into XLl-Blue cells. Plasmid 
DNA was prepared by standard procedures (Sambrook, et al., 
1989). The plasmid can be used directly to produce capped 
transcripts suitable for in vitro translation (see below) 
and for sequencing as described below. The size of each 
cDNA insert ligated into the plasmid vector, the plasmid 
DNA was digested with EcoR I, separated by agarose gel 
electrophoresis, stained with ethidium bromide, and 
detected using a UV transilluminator. 
2. Nucleotide sequencing and analysis 
Complementary DNA (cDNA) inserts were sequenced in 
both directions by dideoxy (Sanger) sequencing (Sanger et 
al., 1977; Sanger et al., 1980) using a US Biochemical 
Sequenase™ (Cleveland, OH) kit. Following instructions 
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provided with the kit, 3 µg of double stranded plasmid DNA 
was denatured in 0.2 N NaOH for five minutes, by the 
addition of NH4AC to 0.8 M, and precipitated with two 
volumes of absolute ethanol. The DNA was pelleted, washed 
with 70% ethanol, pelleted again, and briefly dried under 
vacuum. 
The oligomer used to prime the elongation reaction 
was annealed to the denatured plasmid by resuspending the 
dried DNA in 7 µl water, 2 µl of 5X Sequenase reaction 
buffer (200 mM Tris-HCl [pH 7.5], 100 mM MgC1 2 , and 250 mM 
NaCl] and 1 µl of primer (0.5 pmol/µl). The mix was 
incubated at 37°c for 15 minutes. The elongation reaction 
was initiated by adding 2 µl labeling buffer (7.5 µM of 
each dCTP, dGTP, and dTTP), 1 µl of 0.1 M DTT, 0.5 µl 
[a35s]-labeled dATP (New England Nuclear, Boston, MA), 
and 2 µl of diluted Sequenase™ (1 unit/µl in 10 mM Tris-
HCl [pH 7.5], 5 mM DTT, and 0.5 mg/ml BSA). The reaction 
was divided into four tubes (labeled A, c, G, and T 
respectively) incubated at room temperature for five 
minutes. Termination was accomplished by adding 2.5 µl of 
the appropriate ddNTP mix (ddATP, ddCTP, ddGTP, or ddTTP) 
into the respective tube and incubating for five minutes 
at 37oc. The sequencing reaction was stopped by the 
addition of 4 µl of stop solution (95% formamide, 20 mM 
EDTA, 0.05% bromophenol blue and 0.05% xylene cyanol FF). 
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Two microliters from each reaction was loaded per 
well (formed using a sharkstooth comb) on an 8% 
acrylamide-urea sequencing gel. Electrophoresis was 
carried out in Tris-boric acid buffer (TBE) at 
approximately 60 watts constant power (sufficient to 
maintain the gel at a constant temperature of 5o0 c). 
Following electrophoresis, gels were fixed in a solution 
of 5% methanol and 5% acetic acid for 15 minutes, during 
which time the urea was removed. The gels were then dried 
(30 minutes at ao0 c) under vacuum using a Hoffer Slab Gel 
dryer (San Francisco, CA) and autoradiographed for 12 to 
24 hours. Each reaction was sufficient to resolve 250 to 
300 base pairs of sequence from the primer. Sequence data 
from both stands of multiple clones was obtained to ensure 
accuracy. Primers specific for ELAG sequences were made 
by the Macromolecular Analysis Facility at Loyola 
University Medical School. 
3. Computer analysis - GCG 
The sequences were compared to the GenBank/EMBL 
genetic sequence data bank using the GCG (Genetics 
Computer Group; University of Wisconsin - Madison) 
software maintained in the Loyola University department of 
Academic Computing. 
D. Confirmation of the 5' terminus 
1. Rescreening the library 
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To isolate insert cDNAs which were to be used as 
probes in Northern blot and other hybridization analyses, 
plasmid DNA was digested with EcoR I and DNA separated on 
a 1% low temperature melting point agarose gel. A 340-bp 
EcoR I fragment (this fragment corresponds to ELAG 1 cDNA 
sequences between positions 61 and 401; see Figures 4 and 
20a) stained with ethidium bromide was localized using a 
hand held long wave ultraviolet light source and excised 
from the gel. The gel was then cut into 3 mm squares and 
placed into preweighed microfuge tubes, diluted with water 
to a concentration of 0.3 g/ml, boiled for seven minutes 
and stored at -2ooc. This DNA was then radiolabeled with 
[a32p]-dATP (ICN, Irvine, CA) using the Prime-a-Gene™ 
labeling kit (Stratagene, La Jolla, CA) in which DNA was 
replicated with Klenow polymerase following initiation 
with random primers. Radiolabeled inserts were then 
separated from non-incorporated nucleotides by G-50 
Sephadex chromatography. 
2. 5' RACE 
Reverse transcription of first strand cDNA was 
initiated with an ELAG sequence specific primer 
reverse/complementary to the coding strand (5'-CATT-
TTCAAAATCTAGCCAGGC-3'; this sequence corresponds to 
"primer 1" illustrated in Figure 5 and is reverse/ 
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complementary to sequence positions 657 through 678 shown 
in Figure 4)). In a standard microfuge tube, 20 ng of 
poly A+ RNA was denatured in the presence of 2 pmol of 
primer 1 at 1ooc in a volume of 14 µl for 10 minutes. The 
denatured RNA/primer mix was immediately chilled on ice 
for one minute then centrifuged for 20 seconds to collect 
the condensation. Preparation of the reaction mixture was 
completed by adding 2 µl of lOx synthesis buffer [200 mM 
Tris-HCl (pH 8.4), 500 mM KCl, 25 mM MgC12 , 1 mg/ml BSA], 
2 µl 0.1 mM OTT, 1 µl 10 mM dNTP mix [10 mM each dATP, 
dCTP, dGTP, dTTP], and 1 µl of Superscript™ reverse 
transcriptase (200 units/µ!). The reaction was incubated 
at 42oc for 30 minutes then stopped by warming to 55°c for 
five minutes. The template RNA was degraded by the 
addition of 1 µl ~. coli RNase H (2 units/µl) and 
incubating at 55°c for an additional 10 minutes. 
The first strand cDNA was separated from the salts, 
unincorporated nucleotides and primers of the reverse 
transcription reaction using the GlassMAx™ spin cartridge 
supplied with the kit. To the 21 µl reverse transcription 
reaction, 95 µl of binding solution [6 M Na!] were added 
and the contents transferred to a GlassMAx™ spin column 
and centrifuged for 20 seconds at 13,000 x g. The 
cartridge was washed three times with 400 µl of ice cold 
wash buffer and washed once with 400 µl of ice cold 70% 
ethanol. The cDNA was eluted by adding 50 µl DEPC 
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(diethyl pyrocarbonate) treated water (pre-warmed to 65°c) 
and by centrifugation at 13,000 x g for 20 seconds. 
The addition of a poly(dC) tail was essential for the 
PCR amplification of the cDNA products. In a sterile 
microfuge tube, 16 µl of purified cDNA were heated for 10 
minutes at 7ooc, chilled on ice for one minute and 
centrifuged to collect the condensation. The tailing 
reaction components were added which include 1 µl lOx 
synthesis buffer (200 mM Tris-HCl [pH 8.4], 500 mM KCl, 25 
mM MgC12 , 1 mg/ml BSA), 2 µl dCTP (2 mM), and 1 µl 
terminal deoxynucleotidyl transferase (TdT; 10 units/µ!). 
The reaction was incubated for 10 minutes at 37oc. The 
TdT was heat inactivated at 10°c for 10 minutes and the 
reaction mixture placed on ice. 
The targeted cDNAs were amplified in a reaction 
containing 5 µl tailed cDNA, 30.5 µl DEPC-treated water, 5 
µl lOx synthesis buffer (200 mM Tris-HCl [pH 8.4], 500 mM 
KCl, 25 mM MgCl2, 1 mg/ml BSA), 1 µl 10 mM dNTP mix (10 mM 
each dATP, dCTP, dGTP, dTTP), 1 µl of a modified ELAG-
specific nested primer (10 µM; 5 1 -CAUCAUCAUCAUGGAAGTGTTTC-
TGATGGTAG-3'; this sequence corresponds to "primer 2 11 in 
Figure 5 and is reverse/complementary to sequence 
positions 315 through 334 shown in Figure 4) and 2 µl of 
Anchor Primer (5'-CUACUACUAGGCCACGCGTCGACTAGTACGGGIIGGGII-
GGGIIG-3'). Four CAU triplet repeats were engineered onto 
the 5' end of the ELAG specific primer to allow for rapid 
cloning into the pAMP-1™ plasmid vector. The reaction 
components were overlaid with oil and heated to 95°C for 
five minutes. Prior to starting the PCR cycles, 5 µl of 
diluted Taq polymerase (0.4 units/µl, Perkin-Elmer Cetus) 
were added to the reaction mixture below the oil. The 
cDNA was amplified for 40 cycles (94°c for 30 seconds, 
55°c for 30 seconds, 12oc for 30 seconds). 
3. Primer extension 
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Characterization of the transcriptional start site by 
primer extension was done following the procedure 
previously described (Makino et al., 1988). Briefly, 2 µg 
of poly A+ enriched RNA was denatured in 8 µl of DEPC 
treated water containing 10 µM methyl mercury for 10 
minutes. The cDNA was reverse transcribed in a 50 µl 
reaction containing the denatured RNA, 10 µl of 5x cDNA 
synthesis buffer (500 mM Tris [pH 8.3], 200 mM KCl, 50 mM 
MgC12 ), 10 µl of dNTP mix (25 mM each dATP, dCTP, dGTP, 
and dTTP; Pharmacia, Piscataway, NJ) and 1 µl of AMV 
reverse transcriptase (2 units/µl; Seikagaku, Rockville, 
MD), 28 mM 2-mercaptoethanol and 1 pmol of 5 1 end-labeled 
primer (5'-GTTTTGCATCTATACCTCTCC-3'; this primer is 
reverse/complementary to the sequence positions 146 
through 126 shown in Figure 4). The reaction was 
incubated for one hour at 42°c, phenol/chloroform 
extracted, ethanol precipitated and resolved on a standard 
sequencing gel. 
The primer was end-labeled following standard 
procedures {Sambrook et al., 1989) using (y-32p]-dATP 
{6000 Ci/mmol; New England Nuclear, Boston, MA). 
II. Analysis of BLAG transcription by reverse 
transcription/polymerase chain reaction 
A. Peripheral blood mononuclear cells 
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All of the cell lines and normal peripheral blood 
lymphocytes were cultured in RPM! 1640 {Hazelton, Lenexa, 
KA) supplemented with 10% fetal calf serum {Sigma, st. 
Louis, MO), 500 units/ml penicillin G {Sigma, St. Louis, 
MO) and 50 µg/ml streptomycin sulfate {Sigma, st. Louis, 
MO). Cultures were maintained in a humidified incubator 
at 37oc with 5% co2 in 25 cm2 or 75 cm2 tissue culture 
flasks or tissue culture plates. 
1. Isolation 
Venous heparinized blood was collected from normal 
donors, diluted 1:1 with RPM! 1640 without serum, and 40 
ml layered onto 10 ml of Histopaque™ {Sigma, st. Louis, 
MO) separation medium. The tube was centrifuged at 600 x 
g and the layer containing the white blood cells collected 
and washed in RPM! 1640. Cell pellets were then either 
frozen at -a5oc for RNA extraction from resting cells, or 
cultured in vitro as described below. 
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2. Activation 
Mononuclear peripheral blood cells were aliquoted in 
24 well tissue culture cluster plates (Costar, Cambridge, 
MA) at a concentration of 1 x 106 cells/ml RPM! 1640 
supplemented with 10% heat inactivated fetal calf serum 
and incubated at 37oc with 5% co2 with either 10 µg/ml of 
phytohemagglutinin (PHA; Sigma, st. Louis, MO) or 50 µg/ml 
anti-human Leu-4 monoclonal antibody (Becton-Dickenson, 
San Jose, CA) which specifically binds to the CDJ molecule 
(also referred to as anti-CDJ in this paper). These 
concentrations were previously determined to affect the 
optimal cellular proliferation as measured by [JH]-
thymidine uptake analysis. 
Cells from the Jurkat human T cell leukemic line were 
incubated with the tumor promoter phorbol 12-myristate 13-
acetate (PMA; Sigma, St. Louis, MO) at a standard 
concentration of 10 ng/ml, PHA (Sigma; St. Louis, MO) at 
10 µg/ml or both at the concentrations indicated. Cells 
were harvest at four hours or 24 hours following 
stimulation of the cells, washed in phosphate buffered 
saline, and used for RNA isolation. 
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B. Reverse transcription/Polymerase chain reacti~n -
CRT/PCR) 
1. RNA preparation 
For all procedures involving RNA, steps wer~ taken to 
minimize degradation of RNA by treating all solutions witb 
DEPC followed by autoclaving and by baking all glassware 
at 25ooc overnight. 
Poly A+ RNA used in the RT/PCR studies was lsolated 
from cell pellets using the QuickPrep™ Micro ~A 
purification kit from Pharmacia (Piscataway, NJ) following 
the suggested protocol. Briefly, a cell pellet ~ontaining 
107 cells was lysed in 400 µl of Extraction buff~r 
(aqueous solution containing guanidinium thiocyanate and 
N-lauroylsarcosine), and vortexed vigorously for one 
minute. The cell lysate was diluted in 800 µl of Elution 
buffer (10 mM Tris-HCl (pH 7.4], 1 mM EDTA), and vortexed 
for an additional minute. The lysate was cleareq by 
centrifugation at 13,000 x g for one minute and the 
cleared homogenate was added to an oligo(dT)-cellulose 
pellet prepared from 1 ml of slurry. The homogenate and 
oligo(dT) were mixed thoroughly for three minutes to 
ensure efficient binding of RNA to the oligo(dT). The 
oligo(dT) was pelleted, washed five times with high salt 
buffer (10 mM Tris-HCl (pH 7.4], 1 mM EDTA, 0.5 M NaCl), 
twice with a low salt buffer (10 mM Tris-HCl [pH 7.4], 1 
mM EDTA, 0.1 M NaCl), and transferred to a MicroSpin™ 
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column. The pellet was washed an additional two times in 
the column. The RNA was eluted by adding 70 µl of 65°c 
elution buffer and centrifugation for five seconds at 
13,000 x g. The elution was repeated two more times to 
ensure efficient removal of RNA. RNA was stored at -a5°c. 
2. Reverse transcription - cDNA synthesis 
Complementary DNA (cDNA) was synthesized from cell 
lines as well as resting and activated PBMCs using 
modifications of standard protocols. Twenty micrograms of 
poly A+ RNA was denatured in 11 µl of water and 1 µl of 
random hexamers (1 µg/µl; Pharmacia, Piscataway, NJ) at 
10°c for 10 minutes, then chilled on ice for one minute 
and centrifuged briefly to collect the condensation. 
Reverse transcription was initiated by adding 4 µl of 5x 
reaction buffer (500 mM Tris [pH 8.3], 200 mM KCl, 50 mM 
MgCl2) 1 2 µl of dNTP mix (25 mM each dATP, dCTP, dGTP, and 
dTTP; Pharmacia, Piscataway, NJ) and 1 µl of AMV reverse 
transcriptase (2 units/µ!; Seikagaku, Rockville, MD) and 
incubated at 42oc for 30 minutes. The reaction was 
terminated by heating to 1ooc for five minutes. A control 
reaction was prepared for each RNA sample tested by 
assembling a standard reaction mixture and replacing 
reverse transcriptase with water. 
3. Polymerase chain reaction 
Polymerase chain reaction (PCR) was done following 
standard protocols with commercially available reagents. 
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To enhance the efficiency and specificity of the reaction, 
a hot start was used. In the hot start procedure, each 
reaction was assembled in a 0.5 ml PCR tube and contains 
10 µl of lOx synthesis buffer (100 mM Tris-HCl [pH 9.0 at 
25oc, 500 mM KCl, 1% triton x-100), 16 µl of MgC12 , 8 µl 
of dNTP mix (10 mM each d.ATP, dCTP, dGTP, and dTTP; 
Pharmacia, Piscataway, NJ), 1 µl of primer 1 (10 µM; 5'-
TCCCATCAAGCAGAGAAGTAG-31), 1 µl of primer 2 (10 µM; 5'-
CCAGTTGGAAAGTGTTTCTGATG-31). The efficiency of each 
reaction is highly dependent of the concentration of Mg++, 
which I empirically determined to be 4 mM for the 
reactions done in this lab. Each reaction was covered 
with an Ampliwax™ pellet (Perkin-Elmer Cetus, Norwalk, 
CT), heated to aooc for three minutes to melt the wax, 
then cooled to room temperature to solidify the wax. Each 
reaction mix was covered with 56 µl of water and 5 µl 
diluted Taq polymerase (Promega, Madison, WI) and 5 µl of 
cDNA. As a control to determine that cDNA was made from 
each RNA sample, 5 µl of cDNA was amplified using primers 
(5'-GCCTGCCGTGTGAACCACGTGAC-3' and 5'-TACCTGTGGAGCAACCTGC-
TCAGA-31) which amplify a 277-bp segment of the Beta-2-
microglobulin gene (Lu et al., 1992). All amplification 
programs were initiated with a five minute incubation at 
95oc to fully denature the cDNA template and primers. The 
standard program used for the RT/PCR experiments described 
in this study was a three temperature cycle (95oc for 30 
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seconds, 55oc for 30 seconds, and 12°c for 30 seconds). 
The program concludes with a 10 minute incubation at 12°c 
to ensure that all reactions are completed. Each reaction 
was supplemented with 1 µCi (a32p]-dATP (3000 Ci/mmol; New 
England Nuclear, Boston, MA) to label the amplified 
fragments of DNA. Products were separated by 
electrophoresis on a 2% agarose gel, dried, and 
autoradiographed using an enhancing screen at -as0 c. 
The linear range of amplification for the 277-bp 
Beta-2-microglobulin segment and the 326-bp ELAG segment 
from L428 cDNA were empirically determined following an 
established protocol (Higuchi, 1990). I determined that 
the linear range of amplification for Beta-2-microglobulin 
is between 22 and 30 cycles, while the linear range of 
amplification of ELAG expressed in L428 cells is between 
22 and 32 cycles. All PCR reactions initiated to 
specifically amplify a segment of the Beta-2-microglobulin 
gene were amplified for 30 cycles. However, it was 
necessary to amplify ELAG products from activated PBMCs 
for 36 cycles because of the relatively low level of ELAG 
expression. 
4. Southern blot hybridization. 
PCR amplification of the ELAG specific segment was 
carried out as described above except that the reaction 
was done in the absence of radiolabeled dATP. PCR 
products were separated by agarose gel electrophoresis 
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using standard methodology (Sambrook et al., 1989). 
Following electrophoresis, the gel was denatured with 50 
mM NaOH for 30 minutes, neutralized in 0.1 M Tris-HCl (pH 
7.0) for 30 minutes and the DNA transferred to GeneScreen 
Plus™ (NEN, Boston, MA) using a vacuum transfer apparatus 
and lOX SSC. The blots were denatured for 60 seconds in 
50 mM NaOH, neutralized, and dried. The membrane was then 
incubated in pre-hybridization buff er containing 50% 
formamide, 0.5 M NaCl, 10% dextran sulfate, and 20 µg per 
milliliter denatured salmon sperm DNA for at least one 
hour at 42°c. The buffer was changed and the blots 
hybridized with radiolabeled probes prepared from a 340-bp 
EcoR fragment of ELAG cDNA. Blots were washed in several 
changes of 2X SSC and 0.1% sos at room temperature, and at 
65°c in O.lX SSC and 0.1% sos. Autoradiography was done 
to detect ELAG hybridizing genomic fragments. 
III. Characterization of the putative ELAG-enooded 
protein 
A. Computer analysis 
Analysis of open reading frames and structural motifs 
was done using the MacVector software (IBI, New Haven, 
CT). 
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B. In vitro translation 
The ELAG transcripts were synthesized from linearized 
plasmid containing cDNA which encodes the ELAG open 
reading frame. The cDNA inserts were cloned into the 
pGEM™ (Promega, Madison, WI) vector and sequenced to 
determine that transcription from the T7 RNA polymerase 
promoter would produce the sense RNA strand. The plasmid 
was linearized by standard restriction digest using Sal I 
which will cleave the plasmid in the polylinker region on 
the 3 1 end of the insert. Digested plasmid was analyzed 
by electrophoresis on 1% agarose gel to verify the absence 
of detectable non-linearized DNA. 
In an RNAse-free microfuge tube, 1 µg of linearized 
DNA template was combined with 2 µl of 2.5 mM 
m7G(5')ppp(5')G cap analog (New England Biolabs, Beverly, 
MA), 4 µl of 5x buffer (200 mM Tris-HCl [pH 7.9], 30 mM 
Mgcl2 , 10 mM spermidine, and 50 mM NaCl), 2 µl of 0.1 M 
DTT, 3 µl of a nucleotide mix (which was 2 µM of ATP, CTP, 
and UTP), 1 µl of 0.25 mM GTP, 0.5 µl RNasin, and 1 µl of 
T7 RNA polymerase (20 units/µ!; Promega, Madison, WI) and 
incubated for one hour at 37°c. The concentration of GTP 
was critical to efficient capping and was empirically 
determined in our laboratory. The amount of transcript 
was estimated by electrophoresis in a 1% formaldehyde 
containing agarose gel and staining with ethidium bromide. 
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The in vitro translation was performed using a wheat 
germ translation system (Promega, Madison, WI) following 
the manufacturer's suggested protocol. A 50 µl reaction 
was assembled in an RNAse-free microfuge tube. Five 
hundred nanograms of RNA was denatured at 10°c for 10 
minutes then immediately chilled on ice. The components 
of the translation reaction were added which include 25 µl 
of wheat germ extract (in a buffer containing 107.5 mM 
potassium acetate, 4.2 mM magnesium acetate, 5 mM 2-
mercaptoethanol, 10 mM DTT, 0.1 mg/ml tRNA, 1 mM 
spermidine, HEPES (pH 7.5; the concentration of HEPES 
buffer in the lysate is not provided by the company), 4 µl 
of a 1 mM amino acid mixture minus cysteine, 2.5 µl [35s]-
cysteine (1200 Ci/mmole; New England Nuclear, Boston, MA), 
0.5 µl RNasin (40 units/µ!), and 15.5 µl DEPC-treated 
water. The reaction was incubated at 25oc for one hour 
and terminated by adding 50 µl of 2X Laemli sample buffer. 
c. Mutagenesis 
To test the ability of CUG to serve as the ELAG 
translation initiation site, a CUG to TTA mutation in the 
translational start site was created using a primer 
mediated mutagenesis (Higuchi et al., 1988; Higuchi, 
1990). The procedure is illustrated in Figure 14. 
Primers B (5'-GGGTGAGCAGAGTTACCAAGAGCAAAA-3 1 ) and c (5'-
TTTTGCTCTTGGTAACTCTGCTCACCC-3') are complementary to each 
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other; identical to the double stranded DNA between 
positions 43 to 67 except that the CTG at position 55 was 
changed to TTA on primer B. Likewise, the CAG (reverse 
complimentary to CTG) was changed to TAA (reverse 
complimentary to TTA) on primer c. In the first two PCR 
reactions primers A and B were used in a single reaction 
while primers c and D were used in the other reaction. 
The expected products would overlap and contain the 
substitutions that allow for the CTG to TTA change. The 
PCR products were purified to remove unincorporated 
nucleotides and primers by gel purification and elution 
with the Magic PCR Prep™ system (Promega, Madison, WI). 
The purification was done by electrophoresis in a 1% low 
melting temperature gel. The ethidium bromide stained 
bands were excised, melted at 10°c for five minutes, then 
diluted in 1 ml of PCR Prep resin (resin containing 7 M 
guanidinium thiocyanate, and glass beads.). The slurry 
was collected in a column by vacuum and washed with 70% 
isopropyl alcohol. The DNA was eluted with 5 µl of water 
and centrifuged at 16,000 x g for 30 seconds. The 
purified PCR products were introduced into a single PCR 
(steps 2 and 3) reaction containing the outside primers; A 
and D. The mutated cDNA was purified again by gel 
electrophoresis and separation from the agarose using 
Magic PCR Prep™ (Promega, Madison, WI). Purified cDNA 
was subcloned into the pGEM™ PCR cloning vector (Promega, 
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Madison, WI) in a ligation reaction containing 10 ng of 
PCR product, 1 µl of vector (10 ng/µl) 1 µl of lOx ligase 
buffer (300 mM Tris-HCl [pH 7.5], 100 mM MgC12 , 100 mM 
OTT, 10 mM ATP), 1 µl of T4 DNA ligase, and water to a 
final volume of 10 µl. The ligation reaction was 
incubated at 14oc overnight, then used to transform 
competent ~. coli cells by standard protocol. The 
subcloned cDNA insert was sequenced to confirm that the 
intended bases were mutated. 
IV. Characterization of the transformation potential of 
ELAG 
A. 3 1 RACE 
In an effort to compare the sequences of the ELAG 
transcripts expressed in normal activated cells versus the 
transformed Hodgkin's-disease cells, cDNA clones were 
isolated using 3' RACE (Rapid Amplification of cDNA Ends). 
Reverse transcription of the first strand cDNA was 
initiated with a modified poly(dT) primer designated as 
the Adapter Primer (5'-GGCCACGCGTCGACTAGTAC(T) 17-3
1 ). The 
Adapter primer (1 µl of a 10 mM solution) was added to 20 
ng of poly A+ RNA in a total volume of 14 µl and denatured 
at 10°c for 10 minutes. The mixture was chilled on ice 
for one minute and centrifuged to collect the 
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condensation. The remaining reaction components were 
added which include 2 µl of lOx synthesis buffer, [200 mM 
Tris-HCl (pH 8.4), 500 mM KCl, 25 mM MgC12 , 1 mg/ml BSA], 
2 µl 0.1 mM OTT, 1 µl 10 mM dNTP mix [10 mM each dATP, 
dCTP, dGTP, dTTP], and 1 µl of Superscript™ reverse 
transcriptase (200 units/µl). The RNA template was 
degraded by adding 1 µl of ~- coli RNAse H (2 units/µl) 
and incubated at 42°c for an additional 10 minutes. The 
condensation was collected by quick centrifugation. 
The target cDNA was amplified in a reaction mixture 
containing 5 µl of first strand cDNA, 39.5 µl DEPC-treated 
water, 5 µl lOx synthesis buffer (200 mM Tris-HCl [pH 
8.4], 500 mM KCl, 25 mM MgCl2, 1 mg/ml BSA), 1 µl of 10 mM 
dNTP mix 1 µl 10 mM dNTP mix (10 mM each dATP, dCTP, dGTP, 
dTTP), 1 µl of an ELAG-specific primer (5'-CAUCAUCAUCAUG-
CAAAAAGAAACCATTCATATC-3'; primer 1 illustrated in Figure 
17 and contains ELAG sequences identical to sequence 
positions 64 through 85 shown in Figure 4) prepared as a 
10 µM solution, and 2 µl of the Universal Amplification 
Primer (10 µM, 5'-CUACUACUACUAGGCCACGCGTCGACTAGTAC-3 1 , 
BRL, Bethesda, MD). Four CAU triplet repeats were 
engineered onto the 5' end of the ELAG-specific primer to 
allow for rapid cloning into the pAMP-1™ plasmid vector. 
The reaction components were overlaid with oil and heated 
to 95°c for five minutes. Prior to starting the PCR 
cycles, 5 µl of diluted Taq polymerase (0.4 units/µl, 
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Perkin-Elmer Cetus, Norwalk, CT) were added to the 
reaction mixture below the oil. The cDNA was amplified 
for 40 cycles (94°c 30 seconds, 55oc for 30 seconds, 12°c 
for 30 seconds). 
The RACE products were cloned into the pAMP-1 vector 
using the CloneAmp™ system (Gibco BRL, Bethesda, MD). 
The plasmid pAMP-1 (1 µl containing approximately 50 ng) 
was combined with 8 µl of amplified product from either a 
5' or a 3' RACE reaction in a sterile microfuge tube. To 
the mixture, 1 µl of uracil DNA glycosylase (1 unit/µl) 
was added and incubated for 30 minutes at 37oc. Following 
the subcloning procedure, 1 µl of the ligation mixture was 
used to transform competent bacteria. Clones containing 
the ELAG DNA were identified by hybridization with an ELAG 
probe, analyzed by restriction digest and gel 
electrophoresis. 
B. 5' RACE 
The 5' terminal sequences of each clone isolated were 
confirmed by 5' RACE using the same procedure as described 
in section I.D.2 of the Materials and Methods. The primer 
used in this procedure to initiate reverse transcription 
was 5'-TCCTCCAATGCAAGATCC-3' which is reverse 
complementary to sequence positions 488 through 505 as 
shown in Figure 18. The ELAG primer used to amplify cDNA 
products was 5'-CAUCAUCAUCAUGAATCACACATTGCATCGAG-3 1 which 
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contains sequences that are reverse/complementary to 
sequence positions 462 through 481 as shown in Figure 18. 
c. Northern blot analysis 
1. Isolation of RNA 
Whole cell RNA was extracted using modifications of 
the procedure originally described previously (Chirgwin et 
al., 1979). Briefly, cell pellets were lysed in buffer 
containing 4 M guanidinium thiocyanate (Fluka, Ronkonkoma, 
NY), 0.5% sodium N-lauroylsarcosine, 25 mM sodium citrate, 
and 0.1 M 2-mercaptoethanol, and lysate was then layered 
over a 5.7 M CsCl (Schwartz-Mann, Cleveland, OH) cushion. 
The RNA was pelleted through the CsCl at 30,000 RPM in a 
SW41 Beckman rotor for 24 hours. The RNA pellet was dried 
and washed by ethanol precipitation. Concentration of the 
RNA was estimated by spectrophotometric analysis. 
Definitive analysis of the quality of RNA was determined 
by separating the RNA on formaldehyde containing agarose 
gels and stained with ethidium bromide to detect the 28S 
and 18S ribosomal bands. 
Poly A+ RNA was enriched from RNA preparations by 
oligo(dT) affinity chromatography using procedures as 
adapted in our laboratory. The whole RNA was resuspended 
in 2 ml loading buffer containing 10 mM Tris (pH 7.0), 10 
mM EDTA, 0.5% SOS, and 0.5 M NaCl and applied to a 
oligo(dT) cellulose (BRL, Bethesda, MD) column 
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equilibrated in the same buffer. The solution containing 
RNA was added to the column, the effluent collected and 
added back to the column. The effluent following this 
step was discarded. The column resin was washed 
extensively with the loading buffer. The bound mRNA 
fraction was eluted with buffer containing 10 mM Tris (pH 
7.0), 0.05% sos and 1 mM EDTA, peak fractions pooled, and 
the mRNA precipitated with 0.2 M NaCl and ethanol at -asoc 
for one hour. The oligo(dT) resin was regenerated with 
0.2 N NaOH and washed in loading buffer. The mRNA was 
collected by centrifugation, dried, resuspended in loading 
buffer, and chromatography was repeated as before. 
Enrichment of mRNA was assessed by formaldehyde containing 
agarose gel electrophoresis of whole RNA, the effluent 
ribosomal fraction, and the poly A+ enriched RNA fraction. 
RNA was detected by ethidium bromide staining and the use 
of a UV transilluminator. I was typically able to achieve 
greater than 90% enrichment of poly A+ RNA and used this 
procedure to isolate RNA for the production of the L428 
cDNA library. 
2. Formaldehyde gel electrophoresis 
The quality of RNA preparations was determined by 
electrophoresis through formaldehyde containing agarose 
gels following protocols outlined previously (Sambrook et 
al., 1989). Briefly, a 100 ml agarose (1% w/v) gel was 
prepared by melting 1 g of agarose in 74 ml of water. The 
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agarose was allowed to cool to 6ooc, then 10 ml of lOX 
MOPS buffer (0.2 M MOPS [pH 7.0], 80 mM sodium acetate, 
and 10 mM EDTA [pH 8.0]), and 16 ml formaldehyde (final 
concentration was 2.2 M) were added. Gels were run at 100 
volts in a lX MOPS buffer with constant recirculation to 
maintain pH. The RNA was denatured in 50% formamide, 2.2 
M formaldehyde, and lX MOPS for 10 minutes at 65°c. After 
a denaturing step, lOX loading buffer (50% glycerol, 1 mM 
EDTA [pH 8.0], 0.25% bromophenol blue, and 0.25% xylene 
cyanol FF) was added to each sample. 
3. Transfer and process 
The procedure used in our laboratory for northern 
blot analysis was a modification of standard procedures 
(Sambrook et al., 1989). Briefly, poly A+ RNA was 
transferred from the formaldehyde gel onto a piece of 
GeneScreen Plus™ (NEN, Boston, MA) using a vacuum blot 
transfer apparatus and lOX SSC. Total transfer was 
achieved in two hours. To remove formaldehyde and 
renature the RNA, the membrane was then washed at room 
temperature in 50 mM NaOH for 15 seconds, and then 
neutralized in buffer containing lX SSC and 200 mM Tris 
(pH 8.0) for 30 seconds. The membrane was incubated in a 
prehybridization solution containing 1 M NaCl, 1% sos, and 
10% dextran sulfate for one hour at 65oc. Hybridization 
was done in fresh prehybridization solution supplemented 
with 50 µg/ml sheared salmon sperm DNA and [32p]-labeled 
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probe (1 x 106 cpm/ml) for 12 to 18 hours at 65oc. Blots 
were washed twice in buffer containing 2X SSC, 0.1% SOS at 
room temperature for 10 minutes, twice in the same buffer 
at 65°c for 20 minutes, and once in buffer containing O.lX 
SSC, 0.1% SOS at 65oc for 10 minutes. Washed filters were 
then exposed to X-ray film with intensifying screens at -
85°c. 
v. Transcriptional control of ELAG 
A. Screening the genomic library 
The genomic library prepared from the WI-38 human 
lung fibroblast cell line was purchased from Stratagene. 
The library was packaged in the Lambda Fix™ vector. The 
library was screened following the procedure described in 
section I.B.3 of Materials and Methods in which a 340-bp 
EcoR I fragment from ELAG 1 was radiolabeled and used as a 
probe. This fragment (from sequence position 58 to 398 
shown in Figure 4) contains most of the open reading 
frame. Plaque purified clones were amplified and the DNA 
was harvested by the following method. The KH803 strain 
of~. coli was infected with the phage at a 200:1 bacteria 
to phage ratio in a 3 ml culture, and incubated while 
shaking at 37°c for 20 minutes. The culture was added to 
500 ml NZCYM broth in a 2L flask. This large culture was 
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incubated at 37oc with shaking for approximately 10 hours 
until complete lysis was observed. NaCl was then 
dissolved to a final concentration of 1 molar and the 
culture chilled on ice for one hour. The lysate was 
cleared by centrifugation at 16,000 x g for 10 minutes at 
4oc. Phage were precipitated by adding polyethylene 
glycol to the supernatant and chilling on ice. The 
precipitate was pelleted by centrifugation at 16,000 x g 
for 10 minutes at 4oc. The supernatant was discarded and 
the pelleted phage particles were resuspended in 10 ml of 
SM and 7.5 g of cesium chloride was dissolved. The 
suspension was centrifuged at 150,000g for 24 hours. The 
phage band was removed from the gradient and dialyzed 
against a buffer containing 500 mM Tris-HCl (pH 7.7), 25 
mM KCl, and 0.5 mM MgC12 . The phage were then lysed by 
adding EDTA, sos and Proteinase K (to a final 
concentration of 50 mM, 0.5% and 100 µg/ml respectively) 
and incubating at room temperature for 30 minutes. The 
mixture was phenol/chloroform extracted and ethanol 
precipitated by adding sodium acetate to a concentration 
of 300 mM and two volumes of ethanol. The DNA was 
resuspended in T.E. and digested with the various 
restriction enzymes. The restriction fragments were 
separated by electrophoresis in a 1% agarose gel, stained 
with ethidium bromide and analyzed. 
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Restriction fragments containing sequences of 
interest as indicated by hybridization studies were 
subcloned into pBluescript™ by the following protocol. 
Restriction enzyme digested DNA was separated on a 1% low 
melting temperature agarose gel and stained with ethidium 
bromide. The bands of interest, including the 
pBluescript™ vector linearized with the appropriate 
enzyme, were localized using a long wavelength ultraviolet 
light source, and excised. An individual insert was 
ligated into vector DNA in a reaction containing 5 µl of 
water, 1 µl of melted agarose slice containing vector DNA 
(approximately 50 ng), 4 µl of melted agarose slice 
containing the intended insert and warming the tube for 10 
minutes at 37°c. The reaction mixture was completed by 
adding 10 µl of a ligase cocktail containing 10 units of 
T4 DNA ligase, 10 mM OTT, 10 mM ATP and ligase buffer (60 
mM Tris-HCl [pH 7.8], 20 mM Mgcl2). The reactions were 
incubated at 14°c overnight. 
B. Bacterial strains and transformation 
Our laboratory typically transforms ~- coli strains 
XLl-Blue, DH5-a, or JM109 with ligated plasmid DNA. The 
cells were made competent following a standard protocol. 
A single colony was picked from an LB plate (LB + 15 µg/ml 
of tetracycline was used for XLl-Blue) and used to 
inoculate 5 ml of YA (5% Bacto yeast extract, 2% Bacto 
58 
tryptone, 10 mM Mgso4 , pH to 7.6 with KOH) and incubate 
while shaking at 37°c to an O.D.550 = 0.3. The culture 
was added to 100 ml YA in a 1 liter flask and continued 
shaking at 37oc until the culture attained a density of 
O.D.550 = 0.48. The culture was then chilled on ice for 
five minutes and the cells pelleted by centrifugation at 
1000 x g, 4°c, for five minutes. The supernatant was 
removed and the cells were resuspended in 40 ml ice cold 
Tfbl (30 mM KAc, 100 mM KCl, 10 mM CaC12 , 50 mM MnCl2, 15% 
glycerol, pH to 5.8 with acetic acid, sterilized by 
filtration at 0.22µm). Following a five minute incubation 
on ice the cells were again pelleted at 1000 x g at 4°c 
for five minutes. The supernatant was removed and the 
cells were resuspended in 4 ml ice cold Tfb2 (10 mM MOPS 
[pH 6.5], 75 mM CaCl2, 10 mM KCl, 15% glycerol, sterilized 
by filtration at 0.22µm). The cells were incubated on ice 
for an additional 15 minutes then aliquoted, flash frozen 
in liquid nitrogen and stored at -85°c. These cells 
typically have an efficiency of approximately 1 x 107 
cfu/µg of supercoiled DNA. 
Transformation of competent cells was performed by 
standard procedures. Falcon 2054 tubes were pre-chilled 
on ice for two minutes and 50 µl of thawed competent cells 
were added to each tube. Between 1 ng and 100 ng of DNA 
were added to each aliquot and stored on ice for 30 
minutes. The cells heated to 42oc for 90 seconds and 
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returned to ice for an additional two minutes. The cells 
were diluted in 950 µl of soc (2% Bacto tryptone, 0.5% 
yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM 
Mgso4 , 20 mM glucose) and incubated with shaking at 37°c 
for one hour. The cells were then plated on LB (1% 
Bactotryptone, 1% NaCl, 0.5% Bacto Yeast extract) 
containing agar and supplemented with the appropriate 
antibiotic. 
RESULTS 
I. Isolation and sequence of a novel cDNA clone 
A. Screening protocol 
Based on recent evidence associating Epstein-Barr 
virus (EBV) infection with the development of Hodgkin's 
disease (Anagnostopoulos et al., 1989; Weiss et al., 1989; 
Staal et al., 1989; Libetta et al., 1990), I hypothesized 
that the oncogenic events responsible for Hodgkin's 
disease, both EBV associated and non-EBV associated 
Hodgkin's disease, are mediated by aberrant expression of 
cellular genes which are also aberrantly expressed in EBV 
infected non-Hodgkin's lymphoma. My objective therefore, 
was to isolate cellular genes highly expressed in 
association with Hodgkin's disease and EBV infected 
Burkitt•s lymphomas in order to begin elucidating the 
signal transduction pathways responsible for the 
transformation events in Hodgkin's disease. When I 
initiated this study, the CD30 gene had been associated 
with the Hodgkin's disease phenotype and had been shown to 
be expressed in some EBV infected Burkitt's lymphoma 
cells. Therefore, I was interested in isolating this 
gene, or any novel gene potentially involved in the 
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tumorigenic transformation of cells to the Hodgkin's 
disease phenotype. 
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To do so, I developed a screening procedure that 
would identify genes expressed in an EBV negative 
Hodgkin's-disease cell and that are potential cellular 
targets of the EBV encoded nuclear antigen 2 (EBNA 2). 
EBNA 2 is a viral gene important for inducing cellular 
immortalization (Cohen et al., 1989; Cohen et al., 1992). 
The differential screening protocol employed the use of 
three cell lines; L428, Jiyoye, and PJHR-1. Some 
characteristics of these cell lines which are relavant to 
the screening procedure are summarized in Table 1. The 
L428 cell line is an accepted tissue culture derivative of 
the Hodgkin's disease/Reed-Sternberg cell (H/RS) (Drexler 
et al., 1986; Drexler and Minowada, 1992). The cell line 
was derived from the pleural effusion of a Hodgkin's 
disease patient (Schaadt et al., 1980). Several cellular 
proteins commonly associated with Hodgkin's disease are 
expressed by this cell line including CD30 (Schwab et al., 
1982; Stein et al., 1985; Nawrocki et al., 1988) and IL-9 
(Gruss et al., 1992). Characterization of EBNA expression 
shows that the L428 cell line is not infected with EBV 
(Schaadt et al., 1980). The Jiyoye cell line was 
established from an African Burkitt•s lymphoma (Hinuma and 
Grace, 1967). The cell is infected with a strain of EBV 
that encodes EBNA 2. Virus isolated from tissue culture 
TABLE 1 
CELL LINE DESCRIPTION EBV EBNA 2 
L428 Hodgkin's disease 
Jiyoye African Burkitt•s + + 
lymphoma 
P3HR-1 African Burkitt's + 
lymphoma 
Characteristics of the cell lines utilized in the 
differential screening procedure. EBV, Epstein-Barr 
virus; EBNA-2, Epstein-Barr nuclear antigen 2. 
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supernatants of Jiyoye cells infects and immortalizes 
peripheral blood B lymphocytes. The P3HR-1 cell line is a 
tissue culture derivative of the Jiyoye cell line (Hinuma 
and Grace, 1967). These cells are infected with a strain 
of EBV that lacks the gene encoding EBNA 2 due to a 
spontaneous deletion (Jeang and Hayward, 1983; Bornkamm et 
al., 1982). Virus isolated from the tissue culture 
supernatants of P3HR-1 cells can infect peripheral blood B 
lymphocytes, but the infected cells will fail to become 
immortalized (Jeang and Hayward, 1983; Bornkamm et al., 
1982). Additionally, the Hodgkin's-disease related CD30 
is expressed in the Jiyoye cell line but not in the P3HR-1 
cell line. 
The differential screening procedure used is 
diagramed in Figure 1. The cDNA library from the EBV 
negative, Hodgkin's-disease cell line L428 was screened by 
standard protocols with some modifications as described in 
the Materials and Methods section. Duplicate 
nitrocellulose filters were prepared from the library. 
One of the nitrocellulose filter was hybridized with high 
specific activity [32p]-labeled cDNA probes from the 
Jiyoye cell line. The duplicate filter was hybridized 
with cDNA from the P3HR-1 cell line. Following 
hybridization and washing, the nitrocellulose discs were 
autoradiographed. In the hypothetical autoradiographic 
constellation illustrated in Figure 1, the clone in the 
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L42B cONA Library 
~licate lifts 
• • 
e Autoradiogaphy 
• • • • 
FIGURE 1. Schematic diagram of the differential screening 
protocol. The cDNA library prepared from the Hodgkin's-
disease cell line L428 was differentially screened by 
preparing duplicate lifts on nitrocellulose filters, and 
hybridizing one nitrocellulose filter with high specific 
activity cDNA from the Jiyoye and hybridizing the 
duplicate filter with cDNA probes from the PJHR-1 cell 
line. The hypothetical autoradiographs shown in this 
figure illustrate a clone that specifically hybridizes 
with the Jiyoye probe and that would be a target for 
further study. 
center of the filter hybridized with Jiyoye cDNA 
represents a gene expressed in common between Jiyoye and 
L428 but not in PJHR-1. 
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Clones isolated by this method were tested to 
determine if they meet three criteria: 1) I was 
interested in novel genes. One such gene of interest was 
the CDJO gene, which at the time of the screening had not 
been isolated; 2) isolated clones should also be expressed 
in association with Hodgkin's disease and EBV mediated 
transformation; 3) finally, I was interested in clones 
expressed in association with normal lymphoid cell growth, 
not housekeeping genes, since many transformation 
associated genes are normally involved in growth and 
proliferation (Bishop, 1987). 
B. Sequence analysis 
To satisfy the first criteria described above, clones 
isolated by the differential screening procedure were 
partially sequenced. Three clones which were selected 
following three rounds of differential screening were 
rescued into the pBluescript™ plasmid. The cDNA inserts 
were sequenced by the Sanger chain termination method 
using primers for the T7 RNA polymerase promoter on the 
plasmid vector. Sequences were compared with the 
GenBank/EMBL data bases using the GCG computer software. 
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Partial sequences of two clones isolated by differential 
screening are shown in Figure 2. A clone designated as H4 
was compared to the data base and the best match is shown 
in Figure 2A. The results show that the sequence between 
position 3 and 122 were nearly identical to the sequence 
of the HLA-Cw2 heavy chain gene between positions 4013 and 
3840. Only two mismatches were identified (positions 13 
and 101 of the H4 clone). Close analysis of the 
autoradiograph with the actual sequence data from the H4 
clone indicates that these mismatches are potentially due 
to sequencing errors (data not shown). The numerical 
positions of the HLA clone are shown in descending order. 
Additionally, the HLA sequences shown in this figure are 
complementary to published sequences between positions 
3840 and 4013 (Parham et al., 1989). These results taken 
together indicate that the computer generated comparison 
has aligned the partial sequence of the H4 clone with the 
3 1 terminus of the HLA sequence and therefore, H4 is 
probably not a novel clone. 
A clone designated as F2T3 was compared to the data 
base and the best match is shown in Figure 2B. The 
results show that the sequence between position 1 and 88 
were nearly identical to the sequence of the mitochondrial 
encoded cytochrome oxidase III (COIII) gene between 
positions 9990 and 9903. Four mismatches were identified 
(positions 43, 44, 51, and 83 of the F2T3 clone). Close 
A 
B 
H4.Txt check: 6038 from: 1 to 207 
Primate:Hummhcw2b check: 6881 from: 3809 to: 4023 
/Rev.:rse 
Human MHC class I HLA-Cw2 heavy chain gene, complete eds. 6/89 
Gaps: 5 Quality: 118.0 Ratio: 0.678 Score: 122 Width: 5 Lin!ls: +/-6 
. . . 
178 tgtctcaactttatgtgcactgagctgcacacttccttcacttcccctta 129 
: : : ! : : : : : : : : : : : : : : : : : : : : : : : : 
3840 TGTCTCCA.TCTCTGT .•. CTCAACTTTACGTGTACTGAGCTGCAACTT. 3884 
128 acctt •..... ggaaaataagaatctgaa~atacatttg~tttctcaaa~ 85 
! : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : 
3885 .. CTTCCCTACTGAAAATAAGAATCTGAATATAAATTTGTTTTCTCAAAT 3932 
84 atttgctatgagaggttgatggattaatt~aataagtca~ttcctggaa~ 35 
: : : : : : : : : : : : : : : : : : : : : : : ! : : : : : : : : : : : : : : : : : : : : : : : : : 
3933 ATTTGCTATGAGAGGTTGATGGATTAATTAAATAAGTCAATTCCTGGAAG 3982 
34 gtgagagagcaaataaagacctgagaaccttc 3 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
I I I I I I I I I I I I I I I I I I I I I I I I I I I It I 
3983 TTGAGAGAGCAAATAAAGACC.GAGAACCTTC 4013 
F2T3.Txt check: 9755 from: 1 
Organelle:Hummtcg check: 9132 from: 9902 
Human mitochondrion, complete gonome,. 6/89 
Gaps: 2 Quality: 77.6 Ratio: 0.882 Score: 87 
to 88 /Reverse 
to: 16569 
Width: 9 Linits: +/-10 
. . . . 
88 TTTGGC.TCGAAGCCGCCGCCTGATACTGGCAT'l"l'TGTAAGATGTCCTTT 40 
111111 1111111111111111111111111111111 11 11 11 111 
9903 TTTGGC'I'TCGAAGCCGCCGCCTGATACTGGCAT'l"l'TGT.AGATGTGGTI'T 9951 . . 
39 GACTATI'TCTGTATGTCTCCATCTATTGATGAGGGTCTT l 
111111111111111111111111111111111111111 
9952 GACTATI'TCTGTATGTCTCCATCTATTGATGAGGGTCTT 9990 
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FIGURE 2. Partial nucleotide sequences of two clones 
isolated by differential screening of the L428 cDNA 
library compared with sequences in the GeneBank/EMBL data 
base. Panel A. Sequences of the clone designated H4 (base 
pairs 3 to 178) shares the greatest level of homology with 
HLA-Cw2 heavy chain gene sequences (base pairs 4013 to 
3840). Panel B. Sequences of the clone designated F2T3 
(base pairs 1 to 88) shares the greatest level of homology 
with the mitochondrial encoded cytochrome oxidase III gene 
(base pairs 9990 to 9903). 
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analysis of the autoradiograph with the actual sequence 
data from the F2T3 clone indicates that these mismatches 
are potentially due to sequencing errors (data not shown). 
The numerical positions of the COIII clone are shown in 
descending order and the sequences shown in this figure 
are complementary to published sequences of the COIII gene 
(Montoya et al., 1981; Ojala et al., 1981). These results 
taken together indicate that the computer generated 
comparison has aligned the partial sequence of the F2T3 
clone with the 3' terminus of the COIII sequence and 
therefore F2T3 is not likely to be a novel clone. 
However, sequence analysis of a third clone, 
designated ED1T7, suggested that it might be novel. As 
shown in Figure 3, the partial sequence of this clone 
between base positions 1 and 104 was most closely related 
to the Dictyostelium discoideum encoded cyclic nucleotide 
phosphodiesterase between base positions 3486 and 3574. 
The computer generated comparison shows that only 43 of 
104 base pairs of the ED1T7 clone sequence matched the 
sequence of the phosphodiesterase gene. Because this 
clone showed less than 50% sequence identity with the D. 
discoideum phosphodiesterase gene, the ED1T7 clone 
appeared to be novel. A rigorous sequencing analysis was 
done to confirm this observation. The entire nucleotide 
sequence was determined by analyzing multiple 
independently isolated clones from the L428 Hodgkin's-
Edlt7.Txt check: 7929 from: 1 to: 113 
Unannotated:M23449 check: 5327 from: 3470 to: 6372 
Dictyostelium discoideum, cyclic nucleotide phosphodiesterase. 6/89 
Gaps: 3 Quality: 26.9 Ratio: 0.302 Score: 41 Width: 30 Limits: +/-31 
l jjjjjjjtgjjjgjjy·······jjjgfrigactgccaagaatjfjaacj 43 
3486 AAAAAAAAAAAAAAAGATAATTTATT'lTGA •••••..•••••• TCTTTTA 3522 
44 ggtgggaaacccgttgataaaacttttcagctgcaaacatgtgccaaccc 93 
II 1111111 I 1111111 I I 111 I 11 
3523 TGT ••••••••• GTTGATACACCTTTTCATGTTTACACACAAACAAAAAA 3563 
94 ttcaagataaa 104 
I 111111 
3564 CACTCGATAAA 3574 
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FIGURE 3. Partial sequences of the clone designated ED1T7 
{l to 104) shares the greatest level of homology with the 
Dictyostelium discoideum encoded cyclic nucleotide 
phosphodiesterase. 
10 20 30 40 50 60 
AGT CCC ATC AAG CAG AGA AGT AGA CAG CTT CbG GGG AGG CAG GGG TGA GCA GAG CTG CCA 
Leu Pro> 
70 80 90 100 110 120 
AGA GCA AAA AGA AAC CAT TCA TAT CAC CTT AGA TAC CAC GGC TCT TCC TAC TCC AGG TGC 
Arg Ala Lys Arg Asn His Ser Tyr His Leu Arg Tyr His Gly Ser Ser Tyr Ser Arg Cys> 
130 140 150 160 170 180 
TTC CTG GAG AGG TAT AGA me AAA ACT ATA GGA GTC TTT AGA AGA AGC AAC CAG CCG GAC 
Phe Leu Glu Arg Tyr Arg Cys Lys Thr Ile Gly Val Phe Arg Arg Ser Asn Gln Pro Asp> 
190 200 210 220 230 240 
* 
mT CTT GAA ACG CGA TCA GAA AAA GCC AAG AAT AGA GAT GGG GTT GTT CAG GAA AAA TCT 
Cys Leu Glu Thr Arg Ser Glu Lys Ala Lys Asn Arg Asp Gly Val Val Gln Glu Lys Ser> 
250 260 270 280 290 300 
GTG AGG ACC CTC TTT TCT GAA mT Gm AAT CAA mT GAC ATA CGT AGA AGA CCC ACA AGA 
Val Arg Thr Leu Phe Ser Glu Cys Val Asn Gln Cys Asp Ile Arg Arg Arg Pro Thr Arg> 
310 320 330 340 350 360 
TTT TTG AGA ATG TTC TAC CAT CAG AAA CAC TTC CAA CTG GGC CTA AAA GGG ACA GAG ACA 
Phe Leu Arg Met Phe Tyr His Gln Lys His Phe Gln Leu Gly Leu Lys Gly Thr Glu Thr> 
370 380 390 400 410 420 
GAA AAA AAT GAA AGA AGA TTG mA GAC TGC CAG AAT TCT ACA GGT AGG AAA CCC GTT GAT 
Glu Lys Asn Glu Arg Arg Leu> 
AAA ACT TCT CAG cm CAA ACA mT GCC ACC CTT CAA GAT AAA GGA AGC ACC ATC CCG AGA 480 
GCA GAG CTG CAG GTA CAG AGG CAG AGG CCC AAG mT GGG AAC AGA GGA AGA AGT GCA ACC 540 
CAT AGG CAC AGA GGC AGA GGC CCA ATC CAT AGT CCA AGA AAG AAG AGC TAC AGG CCC AAA 600 
GGG mG AGC CCT GAG AAA GAG GAT TAC TGC CAG GCC TTG AAA TAT AAC AGA AAT TTG CCT 660 
GGC TAG ATT TTG AAA Am ATT GGG ACA GGA GAC TCC ATT CCA ATT TCC ATT CTC TCC TTT 720 
TTG AGA CAG AAA TGT cm TAA CTG TTA TCC TAT GCC mT TCC CAC CAT TGT AAT TTG AAA 780 
GCA GAT TAA CTT TTC TGT TTC ACT GGT TCT CAG AGG AAG AGG AAT Tm GCC TCA GGA AAG 840 
ACC ATA CCC AGA GTT TCA CTC ATA CCT GAT TTA GAT GAT CTA AAT GAT AAG CTT mG AAC 900 
TTT mA ACC GAT GAT ATT mA Am AAA TTT TGG ACT TAG GAT TGA TAT AAT GGG TTG AGA 960 
CTT TTG GTA ATG TTA GGA mG GAT GAA TGT CTT TTA CAC ATG AGA CAG ACA TAA ATT TTG 1020 
GGC CAA AGG GCA GAC TCT GGT GGG CTA AGA Gm GCT TCC TAA AAG ACA TAG CCA CAT CCT 1080 
AAT CCC CAA AAC CAT GAA TTT ATC TTA TTT GGA GAA GGG GGC CTT GCA GAT GTA ATT AAG 1140 
TTA AGA CTC ATG AGG TGA GGA GAT TAT CCT GGA GTA ATC TGG GTA GTC CCT AAA AGT CAT 1200 
CAT AAG GAT CCT TAT TAA ACA GAG GCA GAG GCA GAT TAG GTA TAC AGA GGA GGG mA TGT 1260 
GAA GAC ACA GCA GAA AGA GAA ATG TGG CCA TAA GCC AAA AAA TGC CAA TAG CCA CCA AAA 1320 
GGT GGA CGT GGC AAG GAA AGA TTC TCC TCT AGA GCC TCT GGA GGG AGC Am GCT TTG CTG 1380 
CCC TTC AAA AAT GTA AGC AAA TAA GTT TCT GTT GTG TTA AGC CAT CAT ATT ATT GGT GGT 1440 
AAT TTG TTA CAG CAG CCA AAG GAG ATG ATG GAT GCA ATT AGT TGT TAA TAT TTT AAG GAT 1500 
TCT GTA CCT TTT GAA AAT ATT CTG AAG AAA ATC me ATA AAT GGT GCT TCT CAT GTG TGG 1560 
CAG TAA TAT GGC CAA CAA AAG ACC TTA GTG TAA TTT GGT TTC ATA CTA AAA ATG TCA CTA 1620 
TAT ACT TTT TTT GGT GAT ATA CTT TCC AAT CAT CTA AAA CAA AAC TGC AAA mG CTA GAG 1680 
CAG GAC CAT TAC AAA TCT GGG AAA CAA ACC TTT TAA CTC ACT CAA CTA Tm GAA CTT CAT 1740 
GAA AGA CCC TGA AAG GTT TTT TTT TTT TAA TGT TTG mA AAA GCA TGT GGG ATT GCT CTA 1800 
AAT AAA AAT ATA TAA GTT AAA AAA 1824 
FIGURE 4. Complete nucleotide and predicted amino acid 
sequence of the EDl cDNA isolated by differential 
screening of the Hodgkin's-disease cell line L428 cDNA 
library. Base pairs 1 through 55 (underlined) were 
identified using 5' RACE. 
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disease cell line. The full length clone, designated EDl, 
which corresponds to base pair positions 56 through 1824 
on Figure 4, was compared with the data base. The search 
again showed no direct match with any sequences which 
strongly suggested that the cDNA represented a novel gene. 
The complete nucleotide and predicted amino acid sequence 
of this cDNA clone is shown in Figure 4. The sequence of 
the base pairs 1 through 55 were determined using 5 1 RACE 
as described below. 
c. Characterization of the 5 1 terminus of EDl 
In preliminary sequence analysis I could not identify 
an ATG translational start site. Therefore, I speculated 
that the cDNA clone isolated in the differential screening 
procedure was not full length, lacking the sequences at 
the 5' terminus containing an ATG start site. Three 
methods were used to identify and characterize the 5' 
terminus of the EDl cDNA. First, the L428 cDNA library 
was rescreened using EDl specific probes in order to find 
longer cDNA clones. In the second approach I attempted to 
specifically isolate the 5 1 terminus of the EDl clone as 
well as the related clones by RACE (Rapid Amplification of 
cDNA Ends). Finally, primer extension was done to confirm 
the position of the 5 1 terminus. 
1. Rescreening the L428 cDNA library 
The Hodgkin's disease cDNA library was rescreened 
using an EDl specific probe in an effort to identify the 
most full length EDl clones. All of the EDl cDNA clones 
contained similar 5 1 termini but still no ATG 
translational start site was identified. Interestingly, 
several unique clones with sequences related to EDl were 
isolated from the L428 cDNA library. A description of 
these clones and their potential involvement in the 
transformed phenotype will be discussed in section IV of 
the Results. 
2. 5 1 RACE 
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RACE (Rapid Amplification of cDNA Ends) was used as a 
second approach to directly isolate the 5' terminus of the 
EDl cDNA. Figure 5 illustrates the 5' RACE procedure. In 
the first step, cDNA synthesis was initiated with a primer 
(reverse/complementary to base pair positions 657 through 
678 of EDl as shown in Figure 4) specific for the EDl 
clone. The design of the this primer was based on 
sequences obtained from the cDNA clone isolated from the 
L428 Lambda ZAP library. A poly(dC) tail was added to the 
3 1 terminus of the cDNA molecules. The tailed cDNA 
molecule was then PCR amplified using a poly(dG) primer 
and nested primer (reverse/complementary to base pair 
positions 315 through 334 of the EDl sequence as shown in 
Figure 4; this primer has a modified tail that allows for 
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5' RACE 
AAAAAAA 
1 Step 1 AAAAAAA 
( ~ 
1 Step 2 
~ CCC CCC 
1 Step 3 
GGGGGG 
cccccc 0 
FIGURE 5. Schematic diagram of the 5 1 RACE procedure used 
to isolate the 5' terminus of the EDl cDNA. Rapid 
Amplification of cDNA Ends (RACE) was used to isolate the 
5' terminus of the EDl cDNA. In this procedure, cDNA 
synthesis was specifically initiated using an oligomer 
(primer 1) complementary to the coding strand of the 
clone. A poly(dC) tail was added to the 3 1 terminus of 
the synthesized cDNA clones. The tailed clones are PCR 
amplified using a primer containing a poly(dG) segment and 
primer 2 which was complementary to the coding strand. 
PCR products are subcloned and sequenced as described in 
Materials and Methods. 
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rapid cloning into the pAMP-1™ vector which is described 
in the Materials and Methods section) specific for EDl 
sequences. The RACE products were ligated into the pAMP-1 
plasmid vector and sequenced. Sequence analysis of the 
longest RACE clone allowed for the characterization of an 
additional 55 base pairs of EDl cDNA sequence (underlined 
in Figure 4). However, computer analysis showed that this 
additional sequence did not extend the predicted open 
reading frame. 
3. Primer extension demonstrates heterogeneity of the 
transcriptional start site 
Primer extension analysis was done to help confirm 
that the sequences identified in the RACE clone 
represented the 5' terminus of EDl. A primer that 
initiates reverse transcription from position 126 of the 
EDl cDNA (Figure 4) was end labeled. The first strand 
cDNA products were resolved on a sequencing gel next to a 
ladder of the EDl genomic DNA (isolation and 
characterization of the EDl genomic clone is discussed in 
section V of the Results) which show the predicted 
sequence of the transcript in this region (Figure 6). A 
primer extension product (indicated by the arrow in Figure 
6) migrated at the position of the transcription 
initiation site as predicted by 5' RACE (Figure 4). An 
additional five primer extension products were detected. 
This figure is representative of results obtained in two 
replicate experiments. 
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Figure 7 summarizes the results of the 5' RACE and 
primer extension experiments. The triangles point to 
positions on the genomic DNA sequence that are termini of 
the six primer extension products identified in Figure 6. 
The arrows indicate the 5' terminal position of 13 clones 
isolated by 5' RACE as described above. The figure shows 
that two primer extension products (positions +1 and +8) 
align with two distinct 5' termini of the EDl transcripts 
as predicted by RACE. These data strongly suggest a 
heterogeneity of transcriptional initiation. The EDl 
promoter was determined to be TATA-less (described in 
section V of the Results). Heterogeneity of 
transcriptional initiation is a characteristic that has 
been identified with other genes which are controlled by 
TATA-less promoters (Kozmik et al., 1992). 
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A C G T Px 
FIGURE 6. Primer extension analysis of the EDl 
transcriptional start site. cDNA was synthesized from 2 
µg of Poly A+ RNA, isolated from L428 cells using an end 
labeled primer (the primer sequence is described in 
Materials and Methods) that initiates reverse 
transcription at position +120. The synthesized products 
(lane Px) were resolved on an 8% urea containing 
polyacrylamide gel together with the products of a 
sequencing reaction of genomic DNA representing the 
corresponding nucleotide sequences. The arrow indicates 
the position of the predicted transcriptional start site 
(position +1 as shown on Figure 4) as determined by . 5 1 
RACE. 
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RACE 
-20 -10 +1 
I I 
ggcaaaaccaggcctgacccagccagtcccatcaagcagagaagtagacagcttcagggg 
' ' ' ' ' ' 
PRIMER EXTENSION 
FIGURE 7. Comparison between 5' RACE and primer extension 
analysis. Arrows show the positions of the 5' terminal 
nucleotides of 13 clones isolated by 5' RACE. Triangles 
show the positions of six primer extension products. EDl 
sequence containing the transcription initiation regions 
was obtained from a Pst I fragment of a genomic clone 
which is described in section V of the Results {see figure 
22) • 
II. ANALYSIS OF ED1 TRANSCRIPTION BY RT/PCR 
A. Analysis of EDl expression in association with the 
activation of normal peripheral blood mononuclear cells 
78 
The screening protocol used to isolate EDl was 
designed to identify genes that may be involved in the 
oncogenesis of Hodgkin's disease. Most tumor associated 
genes (or proto-oncogenes) tend to be involved in the 
regulation of normal cell growth (Bishop, 1987). 
Therefore, I evaluated the novel EDl clone to determine if 
it fit the second criteria, that the gene be expressed 
during proliferation, not a housekeeping gene. To do so, 
I studied EDl expression in resting and activated 
peripheral blood mononuclear cells (PBMC). Reverse 
transcription/polymerase chain reaction (RT/PCR) was used 
for this study. 
The primers used in the PCR reaction amplify a 326-bp 
segment of EDl sequence (between base pair positions 4 and 
330 as shown in Figure 4) containing most of the open 
reading frame. In a separated PCR reaction, a 277-bp 
segment of the beta-2-microglobulin is amplified from cDNA 
as a control to standardize the amount of cDNA added to 
the PCR reactions. Additionally, mock reverse 
transcription reactions containing no AMV-RT were done for 
each RNA sample tested and amplified to demonstrate that 
any detectable product was amplified from a cDNA template. 
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In most assays, the PCR reaction mixture was supplemented 
with [a32p]-dATP so that the products separated on 
agarose gels could be identified by autoradiography. 
The time course of EDl expression in activated 
lymphoid cells was determined by examining cells 
stimulated in culture with phytohemagglutinin (PHA), a 
polyclonal T cell mitogen, and collected at various time 
points following stimulation. The results are shown in 
Figure 8. The expected 326-bp product was dectected in 
L428 cells (lane 2). No EDl was detected in resting PBMCs 
(lane 4). Upon activation its expression was detectable 
at seven hours following PHA activation (lane 6), but was 
not detectable by 24 hours following stimulation (lane 8), 
nor was it detected in samples harvested at 48 hours (lane 
10) or 72 hours (lane 12) after stimulation. 
Amplification of the 277-bp segment of the Beta-2-
microglobulin gene was of similar intensity for all cDNA 
samples to verify that cDNA was synthesized in every 
reverse transcription reaction. No specific products were 
amplified from mock cDNA reactions (odd numbered lanes) 
verifying that the PCR products detected were specifically 
amplified from cDNA synthesized in the reverse 
transcription reaction. This figure is representative of 
results obtained in seven replicate experiments. 
To determine if the cells were activated by 
stimulation with PHA, [3H]-thymidine incorporation was 
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FIGURE 8. Expression of EDl in normal peripheral blood 
mononuclear cells (PBMCs) activated with PHA 
(phytohemagglutinin). The autoradiograph shows results 
using reverse transcription/polymerase chain reaction 
(RT/PCR) to measure EDl and Beta-2-microglobulin 
transcripts in mRNA isolated from L428 cells (lanes 1 and 
2), resting peripheral blood mononuclear cells (lanes 3 
and 4), and PBMCs activated with in culture supplemented 
with PHA (10 ng/ml) for seven hours (lanes 5 and 6), 24 
hours (lanes 7 and 8), 48 hours (lanes 9 and 10) and 72 
hours (lanes 11 and 12). The cDNA reactions were done 
with (even lanes) and without (control odd lanes) reverse 
transcriptase. All reactions were supplemented with 1 µCi 
[a32p]-dATP (3000 Ci/mmol) and the products were resolved 
by electrophoresis in a 2% agarose gel. Dried gels were 
exposed to X-ray film at -85°c. 
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analyzed to measure DNA synthesis. Stimulated PBMCs 
collected at the various time points were seeded at 4 x 
105 cells/ml and pulsed for four hours with [3H]-
thymidine. The cells were then harvested and [3H]-
thymidine uptake was measured by liquid scintillation 
counting. The results (Table 2) show that the resting 
cells and cells stimulated with PHA for seven hours and 24 
hours demonstrate background levels of thymidine 
incorporation. However, [3H]-thymidine uptake increases 
nearly 40-fold in cells stimulated with PHA for 48 hours. 
This was an expected result for cells which are 
synthesizing DNA prior to proliferation. The values shown 
in this table are representative of results obtained in 
five replicate experiments. Additionally, cells which 
become activated form clumps in culture which are 
observable by light microscopy. Clumping was observed in 
cells cultured with PHA for at least 24 hours (data not 
shown). This clumping was not observed in PBMCs cultured 
for 24 hours in the absence of stimulus. These results 
strongly suggest that the cells had become activated in 
response to the PHA stimulation. 
The monoclonal antibody anti-human Leu-4 (anti-CD3) 
was next used to specifically activate T lymphocytes. 
PBMCs cultured with anti-CD3 were harvested at various 
time points and RT/PCR was done as described previously. 
The results are shown in Figure 9. No EDl expression was 
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TABLE 2 
[3H]-THYMIDINE INCORPORATION 
Hours Mean + SD* 
0 80 + 25 
7 211 + 143 
24 174 ± 55 
48 7841 ± 893 
72 4341 + 1012 
*n = 12 for all time 
points analyzed 
[3H]-Thymidine incorporation values for resting PBMCs and 
for PBMCs activated with phytohemagglutinin (PHA). 
Cultures harvested at the indicated time points were 
pulsed for four hours with 1 µCi [3H]-thymidine per 1 x 
105 cells. Levels of [3H]-thymidine were determined by 
liquid scintillation counting. Twelve samples were 
analyzed for each time point. 
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ED1 + 
31 0 bp-
beta-2-MG ~ 
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FIGURE 9. Expression of EDl in normal peripheral blood 
mononuclear cells activated with anti-CD3 monoclonal 
antibody. The autoradiograph shows results using RT/PCR 
to measure EDl and Beta-2-microglobulin transcripts in 
mRNA isolated from resting peripheral blood mononuclear 
cells (lanes 1 and 2), and cells cultured with anti-CD3 
for two hours (lanes 3 and 4), four hours (lanes 5 and 6), 
six hours (lanes 7 and 8), 12 hours (lanes 9 and 10) and 
24 hours (lanes 11 and 12). The cDNA reactions were done 
with (even lanes) and without (control odd lanes) reverse 
transcriptase. All reactions were supplemented with 1 µCi 
(a32p]-dATP (3000 Ci/mmol) and the products were re~olved 
by electrophoresis on a 2% agarose gel. Dried gels were 
exposed to X-ray film at -a5°c. 
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detected in resting cells (lane 2). However, EDl was 
expressed in cells stimulated with anti-CD3 for two hours 
(lane 4), four hours (lane 6) and for six hours (lane 8) 
but was no longer detectable by 12 hours (lane 10) nor at 
24 hours (lane 12) post activation. Amplification of the 
277-bp segment of the Beta-2-microglobulin gene was of 
similar intensity for all cDNA samples. No specific 
products were amplified from mock cDNA reactions (odd 
numbered lanes) at detectable levels. This figure is 
representative of results obtained in four replicate 
experiments. Cell proliferation was monitored in cells 48 
hours after stimulation by (3H]-thymidine incorporation 
(data not shown). A control was done in which 
unstimulated cells were cultured for four hours in the 
absence of anti-CD3. The cells were collected, RNA 
isolated, and analyzed by RT/PCR. PBMCs culture for four 
hours in the absence of anti-CD3 did not express 
detectable levels of EDl (data Rot shown). 
To more definitively determine the time that EDl 
expression initiates, the experiment was repeated with the 
cells harvested within two hours following activation with 
anti-CD3. The data in Figure 10 shows that EDl was not 
detectable in resting cells (lane 1), or cells harvested 
at either 15 minutes (lane 2) or 30 minutes (lane 3) 
following activation with anti-CD3. However, EDl was 
detected in cells one hour following stimulation (lane 4) 
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FIGURE 10. Expression of EDl in normal peripheral blood 
mononuclear cells activated with anti-CD3. RT/PCR results 
of EDl and Beta-2-microglobulin expression in resting 
cells (lane 1), and cells incubated in culture with anti-
CD3 for 15 minutes (lane 2), 30 minutes (lane 3) 60 
minutes (lane 4) and 120 minutes (lane 5). All reactions 
were supplemented with 1 µCi [a32p]-dATP (3000 Ci/mmol) 
and the products were resolved by electrophoresis on a 2% 
agarose gel. Dried gels were exposed to X-ray film at 
-a5°c. 
and at two hours following stimulation (lane 5). 
Amplification of the 277-bp segment of the Beta-2-
microglobulin gene was of similar intensity for all cDNA 
samples. No specific products were amplified from mock 
cDNA reactions at detectable levels (data not shown). 
This figure is representative of results obtained in two 
replicate experiments. 
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A recent classification scheme devised by Gerald 
Crabtree has categorized genes which are induced to 
expression during T cell activation (Crabtree, 1989; 
Altman et al., 1990). over 100 genes have been identified 
that are considered to be T cell activation genes. These 
genes are grouped into three major categories based on 
when their expression is initiated following activation; 
the immediate early activation genes, which are expressed 
within the first 30 minutes following stimulation; the 
early activation genes, which are expressed between 30 
minutes and 48 hours; and the late genes which are 
expressed after 48 hours. Based on my observations, the 
novel clone should be categorized as an early activation 
gene and therefore, we named it ELAG (Early Lymphoid 
Activation Gene). 
B. ELAG Expression in activated Jurkat cells 
To help confirm that ELAG (Early Lymphoid Activation 
Gene) is expressed in activated T cells, studies were done 
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to evaluate ELAG expression in the Jurkat leukemic T cell 
line. Jurkat cells are an accepted tissue culture line 
for studying T cell activation because upon stimulation 
with two signals, PHA (phytohemagglutinin) and TPA (12-0-
tetradecanoyl phorbol-13-acetate), these cells mimic 
several responses observed in normal activated T cells 
(Gillis and Watson, 1980). Specifically, activated Jurkat 
cells produce and secrete IL-2 in an analogous manner to 
normal activated T cells. Therefore, these studies would 
help to confirm the involvement of T cells and provide 
information about the signals required for ELAG 
expression. The results in Figure 11 show that ELAG 
expression was not detected in Jurkat cells unstimulated 
in culture for four hours (lane 1) or 24 hours (lane 5). 
ELAG expression was detected in cells cultured for four 
hours with either PMA (lane 2) or PHA (lane 3). Jurkat 
cells stimulated with both PHA and PMA for four hours 
expressed ELAG (lane 4) at greater levels than were 
detected when cells were stimulated with either PMA or PHA 
alone. Jurkat cells cultured with PHA and PMA for 24 
hours express barely detectable levels of ELAG (lane 6). 
This figure is representative of results obtained in two 
replicate experiments. IL-2 synthesis in resting and 
stimulated cells was directly measured by ELISA to 
determine if the cells were activated. The results showed 
that unstimulated cells, or cells stimulated with only PHA 
603 bp .. 
ELAG .. 
310 bp + 
beta- 2 -MG ... 
1 2 
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FIGURE 11. RT/PCR analysis of ELAG expression in non-
activated and activated Jurkat cells. ELAG expression in 
non-activated and activated Jurkat cells. RT/PCR was used 
to measure ELAG and Beta-2-microglobulin expression in the 
Jurkat T cell line cultured for four hours in medium alone 
(non-activated, lane 1), or medium supplemented with PHA 
(lane 2), PMA (lane 3), or PHA and PMA (lane 4), and cells 
cultured for 24 hours in medium alone (lane 5) or with 
both PHA and PMA (lane 6). All reactions were 
supplemented with 1 µCi [a32p]-dATP (3000 Ci/mmol) and the 
products were resolved by electrophoresis on a 2% agarose 
gel. Dried gels were exposed to X-ray film at -a5°c. 
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or only PMA did not synthesize IL-2. However, Jurkat 
cells stimulated with both PHA and PMA secreted IL-2 into 
the culture supernatants (data not shown). 
c. PCR products hybridize with an ELAG specific probe 
To determine if the products identified in these 
RT/PCR experiments represented ELAG sequences, PCR 
products were tested by Southern hybridization. To do so, 
cDNA was added to a PCR reaction and amplified in the 
absence of radio-labeled nucleotides. The products were 
separated by agarose gel electrophoresis and transferred 
to a nylon membrane. The membrane was incubated with a 
[a32p]-labeled ELAG probe, washed and autoradiographed. 
The results in Figure 12 show that amplified products from 
L428 cells (lane 2), anti-CD3 activated PBMCs (lane 6), 
and PHA/PMA stimulated Jurkat cells (lane 10) hybridized 
with a radiolabeled ELAG specific probe. However, no 
hybridization was detected in unstimulated PBMC (lane 4) 
or unstimulated Jurkat cells (lane 8). No specific 
products which were amplified from mock cDNA reactions 
hybridized with the ELAG probe at detectable levels (odd 
numbered lanes). This figure is representative of results 
obtained in three replicate experiments. These results 
confirm that ELAG transcripts are expressed upon 
activation of PBMCs or Jurkat cells. 
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FIGURE 12. Hybridization of PCR amplified products with 
an ELAG specific probe. RT/PCR products from various 
cultured cells were separated by electrophoresis through 
1% agarose gel, transferred to a nylon membrane and 
incubated with either a 32P-labeled ELAG probe or a Beta-
2-microglobulin probe. The RT/PCR products analyzed were 
from L428 cells (lanes 1 and 2), resting PBMCs (lanes 3 
and 4), PBMC cultured for four hours with anti-CD3 
antibody (lanes 5 and 6), non-activated Jurkat cells 
(lanes 7 and 8) and PHA/PMA activated Jurkat cells (lane 9 
and 10). The cDNA reactions were done with (even lanes) 
and without (control odd lanes) reverse transcriptase. 
The membrane was washed and autoradiographed at -as0 c. 
III. Properties of the putative ELAG-encoded proteins 
A. Amino acid sequence and putative structure of the 
ELAG-encoded protein 
91 
The predicted amino acid composition of the ELAG open 
reading frame shown in Figure 4 was analyzed for consensus 
protein motifs and is diagrammed in Figure 13. Beginning 
at the N-terminus, the predicted protein contains the 
sequence Pro-Arg-Ala-Lys-Arg (positions 2 through 6) that 
is very similar to known nuclear localization signals 
(Dingwall and Laskey, 1986). Also, this terminus is 
highly basic and lacks any identifiable signal peptide. 
The c-terminus contains a single zinc finger-like motif 
that is related to the TFIIIA zinc finger domain 
(Cx3Cx12Hx2H; cysteine followed by 3 amino acids, a second 
cysteine followed by 12 amino acids, a histidine followed 
by 2 amino acids and a final histidine) originally 
described in Xenopus (Miller et al., 1985; Brown et al., 
1985). The computer also identified four potential sites 
of phosphorylation. There are two serine residues 
(positions 48 and 65) and one threonine residue (position 
102) that are potential substrates of protein kinase-c. 
There is also one serine residue (position 9) that is a 
potential phosphorylation substrate of c-raf. This 
analysis suggest that the ELAG encodes a nuclear 
<r <r ~ ~ 
R/K s s s c x 3 c x14 H x2 H T 
2 9 48 62 70 92 
102 
I I 
Nuclear Localizatton Signal Zinc Finger-like Domain 
FIGURE 13. Structural motifs encoded by the predicted 
ELAG-encoded protein. This diagram shows the protein 
motifs for the deduced open reading frame based on the 
ELAG cDNA sequence (formerly identified as EDl) shown in 
Figure 4. R/K putative nuclear localization signal Pro-
Arg-Ala-Lys-Arg; s, potential serine sites of 
phosphorylation; T, potential sites of threonine 
phosphorylation; Cx3Cx12Hx2H, TFIIIA-like zinc finger 
domain. · 
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phosphoprotein utilizing a single zinc finger which 
potentially binds DNA or RNA. 
B. In vitro translation of the ELAG open reading frame 
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To investigate the possibility that ELAG utilizes a 
CUG translation initiation codon instead of an AUG, I 
tested the ability of the ELAG open reading frame to be 
translated in vitro from sense transcripts encoding wild 
type ELAG sequences versus sense transcripts containing a 
mutation at the putative translation start site. To do 
so, I used a PCR based protocol to create the mutation at 
the putative translational start site to test the 
hypothesis that the CUG (CTG in the cDNA sequence) at 
position 55 (see Figure 4) is necessary for translational 
initiation. The mutational process is illustrated in 
Figure 14. Briefly, three PCR reactions are performed 
using four different primers. One pair of primers 
(primers B and C) are complementary to each other. These 
primers are identical to the double stranded DNA positions 
43 to 67 except that the CTG at position 55 was changed to 
TTA on primer c. Likewise, the CAG (reverse complimentary 
to CTG) was changed to TAA (reverse complimentary to TTA) 
on primer D. In the first two PCR reactions, primers A 
and B were used in a single reaction while primers c and D 
are used in the other reaction. The expected products 
A --
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FIGURE 14. Schematic diagram of the procedure used to 
induce mutations in the putative ELAG translational 
initiation site. The scheme to mutate the putative CUG 
translational start codon to a UUA was done by a two step 
PCR amplification. In the first step, two PCR products 
are synthesized. One product was amplified between Primer 
A and primer c. The other was amplified between primer B 
and primer D. Primers B and c encode a two base mismatch 
that will be incorporated into the final product. The 
products are purified to remove excess primers and added 
to the PCR reaction in the second step in which 
amplification takes place between primers A and D and 
would incorporate the double base mismatch from step 1. 
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would overlap and contain the substitutions that allow for 
the CTG to TTA change. The products of each of the 
reactions were purified to remove the primers. The 
product are combined in a single PCR reaction and 
amplified using primers A and D. The final 
product would contain the sequence change in the full 
length clone. The PCR products were then ligated into the 
pGEM™ PCR cloning vector both under control of the T7 RNA 
polymerase promoter. The mutation was designed to alter 
the CTG at the putative translational start site to a TTA. 
Both CTG and TTA encode leucine so the change will not 
affect the peptide sequence. Sequence analysis of the 
mutant and wild type ELAG clones (Figure 15) shows the 
mutation at positions 55 and 57 to a T and A respectively. 
Sense transcripts from the wild type and mutant cDNA 
inserts were synthesized in vitro and analyzed by 
electrophoresis through a formaldehyde containing agarose 
gel and stained with ethidium bromide to determine the 
relative concentration of transcripts produced by each 
transcription reaction. Equal amounts of wild type and 
mutant transcripts were added to a wheat germ in vitro 
translation system. The translation products were 
separated by SDS-PAGE. As a control, an in vitro 
translation reaction was done in which no RNA was added. 
The results in Figure 16 show that a 13-kDa protein was 
translated in the reaction supplemented with ELAG sense 
c--
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FIGURE 15. The autoradiograph shows the nucleotide 
sequence of the wild type ELAG cDNA compared to the cDNA 
with the mutated translational start site. The Sanger 
sequencing of the subclone mutant PCR fragment is compared 
to the wild type sequence. The mutations C to T and G to 
A are noted with the symbol C•). 
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10.2 kD • 
1 2 3 
FIGURE 16. In vitro translation of wild type and mutant 
ELAG transcripts. The figure shows an autoradiograph of 
an SDS-polyacrylamide gel analyzing wheat germ in vitro 
translation reaction containing no RNA (lane 1), in vitro 
synthesized transcripts encoding wild type ELAG 3 (lane 
2), and in vitro synthesized transcripts encoding ELAG 3 
in which the CUG start codon was mutated to a UAA (lane 
3) • 
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RNA (lane 2) that was not present in the mock translation 
(lane 1). This data is consistent with computer analysis 
of the ELAG open reading frame which predicts that ELAG 
encodes a 13.2-kDa protein. The translation reactions 
that received the mutant transcript (lane 3) shows no 
detectable levels of a 13.2-kDa protein. This figure is 
representative of results obtained in three replicate 
experiments. The data shows that the ELAG-encoded open 
reading frame, without an in-frame AUG, can be translated. 
Additionally, by altering the CUG at sequence position 55 
reduces the translational efficiency to undetectable 
levels, thus indicating that the CUG is the utilized 
translational initiation site for ELAG-enocded protein. 
IV. Characterization of the transformation potential of 
ELAG 
A. Rationale 
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The results described in the previous section 
demonstrate that ELAG is expressed in association with 
normal lymphoid cell growth and proliferation. This is a 
characteristic common to the proto-oncogenes in that they 
are normally involved in the regulation of cell growth and 
proliferation (Bishop, 1987). Therefore, ELAG is a 
candidate gene, like a proto-oncogene, such that when 
perturbed could be involved in the transformed phenotype. 
Proto-oncogenes become involved in the development of the 
transformed phenotype by two major mechanisms: 1) mutation 
which alters the open reading frame and subsequently 
changes the structure and activity of the protein, or 2) 
the proto-oncogene becomes over-expressed (Bishop, 1987). 
I was interested in determining if either alteration 
potentially affects ELAG in Hodgkin's-disease cells or 
other tumor types. 
B. Analysis of potential mutations associated with ELAG 
expressed in the Hodgkin's disease L428 cells 
In order to identify any potential tumor specific 
mutations in ELAG, it was necessary to obtain and sequence 
cDNA clones from normal activated PBMCs and compare them 
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with the sequences of the L428 derived clones. Clones 
were isolated from activated PBMCs using 3' RACE (Rapid 
Amplification of cDNA Ends) as illustrated in Figure 17. 
Poly A+ RNA isolated from anti-CD3 activated PBMCs and 
used as a template in a cDNA reaction. Synthesis of cDNA 
was initiated by priming with a modified poly(dT) primer 
(described in Materials and Methods) that has a 
specifically engineered tail at the 5' terminus. The cDNA 
was amplified in a PCR reaction containing a modified 
ELAG-specif ic primer (ELAG sequences are identical to 
positions 64 through 85 shown on Figure 18; this primer 
has a modified tail that allows for rapid cloning into the 
pAMP-1™ vector which is described in the Materials and 
Methods section), and a primer which is reverse 
complementary to the tail on the modified poly(dT) primer 
(described in Materials and Methods). The RACE products 
were subcloned into pAMP-1™ using procedures described in 
the Materials and Methods. The clones were isolated by 
hybridization using a [32p]-labeled ELAG specific probe. 
Clones isolated by this method were sequenced in both 
directions and are shown in Figure 18 (positions 64 to 
667). Surprisingly, this new clone contained sequences 
not encoded by the EDl-ELAG clone shown in Figure 4. In 
order to characterize the entire clone, 5' RACE was done 
(described previously as shown in Figure 5) using a primer 
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3' RACE 
AAAAAAA 
l Step 1 
AAAAAAA 
TTTTTTT 
l Step 2 
TTTTTTT 
l Step 3 
AAAAAAA 
TTTTTTT 
FIGURE 17. Schematic diagram of the 3 1 RACE procedure 
used to isolate ELAG clones from normal activated PBMCs 
and L428 cells. Reverse transcription of RNA isolated 
from either L428 cells or PBMCs activated in culture for 
four hours with anti-CD3 monoclonal antibody was initiated 
with oligo(dT). The cDNA was amplified using a poly(dA) 
primer and primer 1 which is identical to the coding 
strand of the ELAG and positioned near the amino terminus 
of the open reading frame. The PCR products are subcloned 
and sequenced as described in Materials and Methods. 
10 20 30 40 50 60 
AGT CCC ATC AAG CAG AGA AGT AGA CAG CTT CAG GGG AGG CAG GGG TGA GCA GAG CTG CCA 
AGT CCC ATC AAG CAG AGA AGT AGA CAG CTT CAG GGG AGG CAG GGG TGA GCA GAG CTG CCA 
70 80 90 100 110 120 
AGA GCA AAA AGA AAC CAT TCA TAT CAC CTT AGA TAC CAC GGC TCT TCC TAC TCC AGG TGC 
AGA GCA AAA AGA AAC CAT TCA TAT CAC CTT AGA TAC CAC GGC TCT TCC TAC TCC AGG TGC 
130 140 150 160 170 180 
TTC CTG GAG AGG TAT AGA TGC AAA ACT ATA GGA GTC TTT AGA AGA AGC AAC CAG CCG GAC 
TTC CTG GAG AGG TAT AGA TGC AAA ACT ATA GGA GTC TTT AGA AGA AGC AAC CAG CCG GAC 
190 200 210 220 230 240 
TGT CTT GAA ACG CGA TCA GAA AAA GCC AAG AAT AGA GAT GGG GTT GTT CAG GAA AAA TCT 
TGT CTT GAA ACG CGA TCA GAA AAA GCC AAG AAT AGA GAT GGG GTT GTT CAG GAA AAA TCT 
250 260 270 280 290 300 
GTG AGG ACC CTC TTT TCT GAA TGT GTG AAT CAA TGT GAC ATA CGT AGA AGA CCC ACA AGA 
GTG AGG ACC CTC TTT TCT GAA TGT GTG AAT CAA TGT GAC ATA CGT AGA AGA CCC ACA AGA 
310 320 330 340 350 360 
TTT TTG AGA ATG TTC TAC CAT CAG AAA CAC TTC CAA CTG GGC CTA AAA GGG ACA GAG ACA 
TTT TTG AGA ATG TTC TAC CAT CAG AAA CAC TTC CAA CTG GGC CTA AAA GGG ACA GAG ACA 
370 380 390 400 410 420 
GAA AAA AAA TGA AAG AAG ATT GTG AGA CTG CCA GAA TTC TAC AGT GTA TGC AAT GGT ATG 
GAA AAA AAA TGA AAG AAG ATT GTG AGA CTG CCA GAA TTC TAC AGT GTA TGC AAT GGT ATG 
430 440 450 460 470 480 
AGG AAC TGT TCC ACA TTA AAG GAG ACT AAG AAG ACA TAA CAA CTC GAT GCA ATG TGT GAT 
AGG AAC TGT TCC ACA TTA AAG GAG ACT AAG AAG ACA TAA CAA CTC GAT GCA ATG TGT GAT 
490 500 510 520 530 540 
TCT GGA CTG GAT CTT GCA TTG GAG GAG AAA ATG CTA TAA AAG GTA TCA CTG AGA CAG TTA 
TCT GGA CTG GAT CTT GCA TTG GAG GAG AAA ATG CTA TAA AAG GTA TCA CTG AGA CAG TTA 
550 560 570 580 590 600° 
ACA TCA TTG GAA CAT GGA TGG TTG ATT AGA TGG AAG TAT TAC ATT AAT GAT ACA TTT TCC 
ACA TCA TTG GAA CAT GGA TGG TTG ATT AGA TGG AAG TAT TAC ATT AAT GAT ACA TTT TCC 
610 620 630 640 650 660 
TGA ATT TGG TAA CTT TGC TAT TGT TAC CTA CAC GAA TAC TCT GCT CTA GGA AAC AGT AAT 
TGA ATT TGG TAA CTT TGC TAT TGT TAC CTA CAC GAA TAC TCT GCT CTA GGA AAC AGT AAT 
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FIGURE 18 . Compar·ison of the complete nucleotide 
sequences of the ELAG-related cDNA clone isolated from 
activated PBMCs (Normal) versus the ELAG-related clone 
isolated from L428 cells (Hodgkin's). 5' RACE and 3' RACE 
clones were isolated using mRNA from L428 cells or from 
PBMCs collected four hours after activation with anti-CD3. 
The sequences underlined indicate the only region of 
divergence between the two cDNA clones. 
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(reverse/complementary to sequences at positions 488 
through 505 on Figure 18) to initiate reverse 
transcription. The poly(dG) tailed cDNA products were 
amplified as using a modified poly(dC) primer and a 
modified primer specific to the ELAG-related clone 
(reverse complementary to positions 462 through 481 as 
shown on Figure 18; this primer has a modified tail that 
allows for rapid cloning into the pAMP-1™ vector which is 
described in the Materials and Methods section). The 
sequences obtained from this analysis showed that the 5' 
terminus of the ELAG-related clone was identical to the 5' 
terminus of the EDl-ELAG cDNA shown in Figure 4. 
Since my original objective in this study was to 
search for mutations in the L428 associated clone, it was 
necessary to repeat the 5 1 and 3' RACE procedure using RNA 
isolated from L428 cells in an effort to isolate a clone 
similar to ELAG-related clone from activated PBMCs. Such 
a clone was isolated from L428 cells and sequenced. A 
comparison of the ELAG clone isolated from normal 
activated PBMCs versus the Hodgkin's-disease L428 tumor 
cell line is shown in Figure 18. The results show that 
the sequences of the ELAG-related clone are nearly 
identical. The only differences identified are at the 3' 
terminus. The cDNA clone isolated from normal activated 
PBMCs has an additional five base pairs (underlined in 
Figure 18) not identified on the tumor associated ELAG 
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clone. It is possible that these differences are the 
result of a cloning artifact and do not represent actual 
differences in the sequences of the transcripts. No 
sequence divergence was detected in the computer predicted 
open reading frame. Therefore, the ELAG-related clones 
isolated from activated PBMCs and L428 cells would encode 
the same protein. 
c. ELAG family members from L428 cells 
To date, four distinct but related clones have been 
isolated by the RACE and rescreening the library. These 
clones have all been sequenced and comparison is shown in 
Figure 19. The EDl-ELAG clone originally isolated from 
the Hodgkin's disease L428 cell line by differential 
screening (Figure 4) is now designated as ELAG 1. ELAG 1 
and ELAG 2 were isolated only from the L428 Lambda ZAP™ 
library. The ELAG-related clone isolated from activated 
PBMCs and L428 cells (Figure 18) is now designated as ELAG 
3. ELAG 3 was only isolated by RACE. ELAG 4 was isolated 
from both the cDNA library and by RACE. 
Eight regions of sequence identity (regions A through 
H) have been identified (Figure 19). All segments 
represented by a given letter share 100% sequence 
identity. All clones identified to date encode region A. 
ELAG clones 1, 2, and 3 contain region B. Region c is 
unique to ELAG 1, while regions D and G are unique to ELAG 
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ELAG 1 A B c 
ELAG 2 A B D E F G 
ELAG 3 A B E H 
ELAG 4 A E F 
FIGURE 19. Comparison of the sequences of the four ELAG 
cDNA clones isolated from the L428 cell line. The 
sequence identity shared by each clone is displayed with a 
letter. The 13.2-kDa open reading frame is encoded in 
regions A and B. 
2 and region H is unique to ELAG 3. No unique regions 
were identified in ELAG 4. 
106 
The open reading frame identified by computer 
analysis in ELAG 1 (Figure 4) is encoded in regions A and 
B. Therefore, ELAG clones 1, 2, and 3 all contain the 
same open reading frame, but have different 3' termini. 
ELAG 4 has an open reading frame that is terminated 
shortly after region A. Interestingly, the open reading 
frame contained in region B encodes a zinc finger motif, 
and therefore ELAG 4 protein would not exhibit this 
domain. 
Northern blot analysis was done using restriction 
fragments of ELAG clones as probes to dispel any 
possibility that the ELAG members were cloning artifacts. 
Figure 20A shows a partial restriction enzyme digestion 
map of the ELAG clones used to prepare probes for this 
study. Three probes were used: 1) a 340-bp EcoR I 
fragment of the ELAG 1 clone which contains regions A and 
B and therefore is expected to hybridize to all ELAG 
transcripts, 2) a 668-bp BamH I fragment of ELAG 1 which 
contains only region C and therefore should be specific 
for ELAG 1, and 3) a 1.0-kb EcoR I fragment of ELAG 2 
which contains regions D, E, F and G and therefore is 
expected to hybridize to ELAG 2, ELAG 3 and ELAG 4 
transcripts. 
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FIGURE 20. Northern blot analysis of RNA isolated from 
L428 cells using restriction fragments of ELAG cDNA clones 
as probes. Panel A show partial restriction maps of ELAG 
1 and ELAG 2. Panel B shows the autoradiographs of RNA 
hybridized with the following probes: lane 1, a 340-bp 
EcoR I fragment of ELAG 1 containing regions A (common to 
all ELAG clones identified to date) and B; lane 2, a 668-
bp BamH I fragment of ELAG 1 containing the 3' terminal 
portion of the region C which is ELAG 1 specific; and lane 
3, a 1.1-kb EcoR I fragment of ELAG 2 which contains 
regions D, E, F and G. 
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RNA from L428 cells was separated by electrophoresis 
through a formaldehyde containing agarose gel in three 
replicate lanes, transferred to nylon membrane, incubated 
with [32p]-labeled probes, and autoradiographed. The 
results of the hybridization study are shown in Figure 
20B. A probe containing sequences from regions A (common 
to all clones identified) and B (common to ELAG 1, 2, and 
3) hybridized to two major transcripts, 1.8-kb and 1.3-kb, 
and two minor transcripts, 1.1-kb and 0.9-kb (lane 1). A 
probe specific for ELAG 1, hybridized only to the upper, 
1.8-kb transcript (lane 2). The 1.0-kb EcoR I fragment of 
ELAG 2, which contains regions D, E, F, and G hybridized 
to the 1.3-kb transcript (lane 3). Hybridization with the 
1.1-kb and the 0.9-kb transcripts are barely detectable. 
D. Analysis of ELAG expression in human tumor cell lines 
Since ELAG expression is regulated during T cell 
activation, it is a candidate gene that when 
constitutively expressed or over-expressed may affect the 
cellular phenotype. To test the third criteria that I 
established for evaluating clones isolated by differential 
screening, I wanted to determine if ELAG is aberrantly 
expressed in association with the development of the 
transformed phenotype. To do so, several tumor cell lines 
were tested for ELAG expression by RT/PCR. The data in 
Figure 21 show that the Hodgkin's-disease cell line L428 
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FIGURE 21. Expression of ELAG in human cell lines. 
RT/PCR results of ELAG and Beta-2-microglobulin expression 
in L428 Hodgkin's-disease cells (lanes 1 and 2), EBV-
infected African Burkitt•s lymphoma lines Jiyoye (lanes 3. 
and 4), P3HR-1 (lanes 5 and 6), and Raji (lanes 7 and 8), 
the T cell line HuT 78 (lanes 9 and 10) and the normal 
human fibroblast lin IMR-90 (lanes 11 and 12). cDNA 
reactions were done with (even lanes) or without (odd 
lanes) reverse transcriptase. All reactions were 
supplemented with 1 µCi [a32p]-dATP (3000 Ci/mmol) and the 
products were resolved by electrophoresis on a 2% agarose 
gel. Dried gels were exposed to X-ray film at -85°~. 
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express the highest levels of ELAG (lane 2), while Jiyoye 
cells express small but detectable amounts of ELAG (lane 
4). The P3HR-1 cell line did not express detectable 
levels of ELAG. I predicted this expression profile given 
that the ELAG clone was isolated through a differential 
screening method which targeted genes that are expressed 
in L428 and Jiyoye cells but not in PJHR-1 cells 
(described in section I of the Results). Several other 
cell lines tested do not express detectable levels of ELAG 
including the EBV infected African Burkitt's lymphoma cell 
line, Raji (lane 8); the T cell lymphoma line, HuT 78 
(lane 10); and the normal lung fibroblast line, IMR-90 
(lane 12). This figure is representative of results 
obtained in four replicate experiments. These results 
show the restricted nature of ELAG expression in tumor 
cell lines. Additionally as shown in Figures 11 and 12, 
ELAG is not expressed in unstimulated Jurkat T cell 
leukemic line. Further, ELAG expression was not detected 
in resting PBMC (Figures 8, 9, 10, and 12). Taken 
together, these results suggest that ELAG is 
constitutively expressed only in the Hodgkin's-disease 
cell line L428 and to a lesser degree in the EBV infected 
African Burkitt's lymphoma cell line Jiyoye. 
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v. Transcriptional control of ELAG 
To understand how aberrant signal could potentially 
affect ELAG expression in Hodgkin's-disease cells and to 
understand the molecular basis of the transient expression 
of ELAG in activated T cells, it was necessary to 
investigate the signals involved in the regulation of ELAG 
transcription. To do so, I isolated clones from a WI 38 
human lung fibroblast genomic library and sequenced the 
transcriptional control region. The library was screened 
using probes containing ELAG sequence regions A and B (see 
Figures 19 and 20A). Two overlapping clones, designated 
6-3 and 6-4 (Figure 22), were isolated. Clone 6-3 
contains regions B and c of ELAG 1. Clone 6-4 contains 
region A of ELAG 1 plus the transcriptional control 
region. A 4.5-kb Pst I fragment of the 6-4 clone was 
ligated into pBluescript™ and sequenced upstream to 
position -135, with respect to the designated 
transcriptional initiation site, using ELAG specific 
primers. The sequences surrounding the putative 
transcriptional start site, indicated with an arrow at 
position +1, are shown in Figure 23. This transcriptional 
start site was identified by primer extension and 5 1 RACE 
(Figures 6 and 7). 
No TATA-like element was identified near the expected 
position of -30 from the transcriptional start site. 
ELAG-1 cDNA 
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FIGURE 22. Partial restriction map of the overlapping ELAG 
clones 6-3 and 6-4 which were isolated from the WI-38 
human lung fibroblast genomic library. H, Hind III; s, 
Sac I. 
-126 -116 -106 -96 -86 -76 
* * * * 
AGAGCTCACA GTCCGCTTTG ATGAAA,TTCC ATGTTTCTTA CTTGAAAGGG CTGYACCCAT 
CD28 RB 
-66 -56 -46 -36 -26 -16 
* * * * * * 
GATTAGGACT TCCTCCTCTT GATCAGTGAC TCAGACCTGA GICAGTCAGA AAGCAAAACC 
'l'U: 'l'RE 
-6 15 25 35 45 
* * * * -
AGGCCTGACC CAGCCAGTCC CATCAAGCAG AGAAGTAGAC AGCTTCAGGG GAGGCAGGGG 
INR 
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FIGURE 23. Nucleotide sequence of the putative 
transcriptional control region of the ELAG 1 gene isolated 
from the genomic library derived from the WI-38 human lung 
fibroblast cell line. A map of the 135 base pairs 
immediately 5 1 of the proposed ELAG transcriptional start 
site (arrow) contains the INR at position -11 to +4, two 
tandem TPA response elements (TRE) and a consensus CD28 
receptor element (CD28 RE) binding site. 
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However, sequences surrounding the transcriptional start 
sited share 80% identity with the initiator region (INR) 
originally identified in the murine terminal 
deoxynucleotidyl transferase (TdT) gene (Smale and 
Baltimore, 1989; Smale et al., 1990). Previous studies 
have shown that an INR can independently initiate 
transcription (Smale et al., 1990), therefore, a promoter 
containing this element does not require a TATA-box. The 
putative INR at position -11 through +4 likely allows for 
transcriptional initiation from the adenosine at position 
+1. However, the primer extension analysis data shows a 
heterogeneity of transcriptional initiation (Figures 6 and 
7). Multiple transcriptional start sites have been 
described for other genes controlled by TATA-less 
promoters (Kozmik et al., 1992). 
Two TPA response elements (TRE) are aligned at 
positions -37 and -53 with respect to the transcriptional 
start site (Holbrook and Fornace, 1993; Angel and Karin, 
1991). A consensus CD28 receptor element (Fraser et al., 
1991) (CD28 RE) binding site was identified at position 
-110. 
DISCUSSION 
Isolation of ELAG: A potential cellular target of EBV 
immortalization 
The novel ELAG (early lymphoid activation gene) cDNA 
clone was isolated utilizing a differential screening 
protocol designed to identify genes that are expressed in 
association with lymphoid cell growth and in the 
transformation of cells to the Hodgkin's disease 
phenotype, as well as Epstein-Barr virus (EBV) infected 
Burkitt's lymphoma. The rationale for this study was 
based on the recent studies demonstrating by in situ 
hybridization that the EBV genome is harbored in the Reed-
Sternberg cells of diseased tissue in 25-60% of the 
Hodgkin's disease patients tested (Anagnostopoulos et al., 
1989; Weiss et al., 1989; Staal et al., 1989; Libetta et 
al., 1990). These studies supported a long held 
speculation that EBV may be a causative agent of Hodgkin's 
disease. I hypothesized that the oncogenic events 
responsible for Hodgkin's disease, both EBV associated and 
EBV negative independent Hodgkin's disease, are mediated 
by aberrant expression of cellular genes which are also 
aberrantly expressed in EBV infected non-Hodgkin's 
lymphoma. My objective was to identify genes involved in 
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this putative pathway in order to elucidate the signal 
transduction pathway and biochemical alterations 
responsible for transformation of cells to the Hodgkin's 
disease phenotype. 
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I developed a differential screening procedure (shown 
in Figure 1) designed to identify genes expressed in 
association with Hodgkin's disease and that may be 
cellular targets of the EBV encoded immortalization 
factor, EBNA 2 (Cohen et al., 1989; Cohen et al., 1992). 
Clones isolated by this method were tested to determine if 
they meet three criteria. First, I was interested in 
novel genes. One gene of interest was the CD30 gene which 
is expressed following EBV induced immortalization and its 
expression is associated with Hodgkin's disease. At the 
time of the screening, the CD30 gene had not been 
isolated. Second, I was interested in clones that are 
expressed in association with Hodgkin's disease and EBV 
mediated transformation. Third, I was interested in 
clones which are expressed in association with normal 
lymphoid cells growth, not housekeeping genes. I was 
interested in such genes because most tumor associated 
genes (or proto-oncogenes) tend to be involved in the 
regulation of normal cell growth. 
Several clones isolated by the differential screening 
procedure were sequenced to determine if they met the 
first criteria (Figures 2 and 3). This study showed that 
117 
only one clone demonstrated very low levels of relatedness 
to any sequences in the GenBank/EMBL data bases (Figure 
3), signifying that the clone is likely novel (i.e. 
previously not described). 
Expression of the novel clone was detected in the EBV 
negative L428 Hodgkin's-disease cell line and in the EBV 
infected Jiyoye African Burkitt•s cell line (Figure 21). 
These results are consistent with the involvement of ELAG 
in Hodgkin's disease and Burkitt•s lymphoma. 
Additionally, ELAG was not expressed at detectable levels 
in the P3HR-1 African Burkitt•s lymphoma cell line. This 
was expected in that clones isolated by differential 
screening were selected based on their expression in 
Jiyoye but not P3HR-1 cells. Jiyoye cells are infected 
with a viral strain containing EBNA 2, and the phenotype 
of these cells as indicated by the expression of cell 
surf ace proteins suggest that EBNA 2 has induced the 
expression of cellular genes associated with EBV mediated 
immortalization. P3HR-1 cells, on the other hand, are 
infected with and EBNA 2 negative, non-immortalizing 
strain of EBV. The cellular environment in which ELAG is 
expressed indicates that it is a potential target of EBNA 
2, either directly or indirectly. EBNA 2 is a 
transactivator of cellular genes including CD23 (Wang et 
al., 1990; Wang et al., 1987). It would be interesting to 
determine if cis elements in the transcriptional control 
region of ELAG are substrates of EBNA 2 activity. 
The role of ELAG in normal T cell activation 
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A third criteria that I established to determine if 
clones isolated by differential screening were suitable 
for additional study was that they should be expressed in 
association with normal cell growth and proliferation. I 
was interested in identifying genes which could 
potentially be involved in the development of the 
transformed phenotype of Hodgkin's disease. 
Transformation associated genes {i.e. proto-oncogenes) 
tend to function normally in the regulation of cell growth 
and proliferation {Bishop, 1987). Therefore, if ELAG is 
involved in the oncogenesis of Hodgkin's disease, it would 
likely be involved in the regulation of normal cell 
growth. During a study designed to determine the role of 
ELAG in normal cell growth I demonstrated that the novel 
clone is expressed in association with the activation of T 
lymphocytes in a population of peripheral blood 
mononuclear cells {PBMC; Figures 8, 9, 10 and 12). 
The novel ELAG gene is expressed within one hour 
following activation of PBMC with anti-CD3 monoclonal 
antibody {Figure 10). This antibody specifically 
stimulates T cell activation by binding to the T cell 
receptor/CD3 molecule, also known as the antigen receptor 
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complex. These data strongly suggest that ELAG is 
expressed in activated T cells of the PBMC population. To 
help confirm this observation, ELAG expression was studied 
in Jurkat human leukemic cell line which is an accepted 
tissue culture model for the investigation of events 
during T cell activation. Jurkat cells can be stimulated 
to produce IL-2 by mechanisms that are analogous to those 
in activated T cells (Gillis and Watson, 1980). 
Activation of Jurkat cells requires two signals, 
stimulation of the TCR/CD3 complex coupled with induced 
activation of protein kinase c (Gillis and Watson, 1980). 
In tissue culture, these signals can be provided by the 
addition of PHA (phytohemagglutinin) and PMA (phorbol 12-
myristate 13-acetate, also known as TPA). I found that in 
vitro activation of Jurkat cells with PMA and PHA will 
induce ELAG expression in four hours (Figure 11). These 
data are consistent with the designation of ELAG as a T 
cell activation gene. Furthermore, either of these two 
signals added in culture individually is sufficient to 
induce ELAG expression. In contrast, expression of IL-2 
requires two signals; both PHA and PMA (Gillis and Watson, 
1980). These data indicated the biochemical signals 
required for induction of ELAG expression are less complex 
than the signals required for stimulation of IL-2 
production. Additionally, the AP-1 transcription factor 
is activated by stimulation with PMA (Holbrook and 
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Fornace, 1993; Angel and Karin, 1991). Induction of ELAG 
expression with PMA alone further supports the argument 
that ELAG is an immediate downstream target of AP-1 
transcriptional activator. 
T cell activation is very complex and is poorly 
understood. More than 100 different genes and proteins 
have been identified that are expressed during T cell 
activation (Crabtree, 1989; Altman et al., 1990), and 
their expression is activated in a coordinated manner that 
is tightly regulated (Altman et al., 1990; Ullman et al., 
1990; Furue et al., 1990). The complexity of this cascade 
of genes is highlighted by the recent studies of Zipfel et 
al. who have isolated 60 novel cDNA clones, by subtractive 
screening, which are expressed following T cell activation 
(Zipfel et al., 1990; Irving et al., 1989). These 
investigations support the contention that there are many 
signals involved in T cell activation that are not 
understood. Because ELAG is expressed in activated T 
cells, further study of its properties may provide 
additional information about the molecular events required 
in the immune response and in general in lymphoid cell 
growth and proliferation. 
Crabtree has categorized the cascade of genes 
expressed during T cell activation into three major groups 
(Crabtree, 1989; Ullman et al., 1990); immediate early 
activation genes, early activation genes and late 
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activation genes. Immediate early genes are expressed in 
the first 30 minutes following activation and include c-
fos (Distel and Spiegelman, 1990; Grausz et al., 1986; 
Moore et al., 1986; Gonda and Metcalf, 1984), c-myc (Reed 
et al., 1986; Grausz et al., 1986; Moore et al., 1986; 
Reed et al., 1985; Gonda and Metcalf, 1984), and NF-KB 
(Jamieson et al., 1991). These genes generally are 
involved in transcriptional activation. The second group 
of genes expressed between thirty minutes and forty-eight 
hours are known as the early activation genes. Genes 
expressed after 48 hours are called the late activation 
genes. 
Based on my studies, ELAG is best categorized as an 
early antigen, induced to expression by stimulation with 
anti-CDJ antibody within one hour but is no longer 
detectable by twelve hours post-activation (Figures 9 and 
10). Included in the group of early activation genes are 
the IL-2 receptor (Wakasugi et al., 1985; Leonard et al., 
1984; Nikaido et al., 1984), IL-2 and other interleukins 
(Norma, 1986; Kinashi et al., 1986; Hirano et al., 1986), 
and c-myb (Reed et al., 1986; Stern and Smith, 1986; 
Torelli et al., 1985; Torelli et al., 1985; Thompson et 
al., 1986). The early genes are heterogeneous in their 
function and are expressed prior to DNA synthesis. 
Therefore, they probably act as mediators between the 
immediate early genes and the signals that actually induce 
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DNA synthesis and cell division (Altman et al., 1990). 
Analysis of the transcriptional control region of ELAG 
shows that it contains two TPA Response Elements (TRE; 
Figure 23). The TRE is a consensus binding site for the 
AP-1 transcription factor. AP-1 factor is a heteroduplex 
of Jun and Fos proteins. Expression of Fos is sharply 
increased during T cell activation (Distel and Spiegelman, 
1990; Grausz et al., 1986; Moore et al., 1986; Gonda and 
Metcalf, 1984) prior to the expression of ELAG. The 
presence of TRE elements in the ELAG promoter region, and 
the temporal relationship between the expression of ELAG 
and Fos strongly suggest that ELAG is an immediate 
downstream substrate for the AP-1 factor. The effect of 
AP-1 activity during T cell activation is poorly 
understood because, to date, very few genes expressed 
during T cell activation have been shown to contain a TRE. 
However, it is thought that AP-1 is a critical nuclear 
factor required to induce expression of other cellular 
genes that are necessary to regulate the T cell activation 
cascade. 
The molecular response required to commit to the 
activation cascade is made between 30 minutes and 2 hours. 
The signals required for this event are poorly understood. 
ELAG is expressed in a time that might allow it to provide 
an important signal required for the T cell to commit to 
the activation pathway. Additionally, ELAG is expressed 
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during a period when the activated T cell advances from Go 
to G1 in the cell cycle. IL-2, which is expressed between 
1 and 24 hours following T cell activation, has been shown 
to be essential for inducing the T cells to enter cell 
division. Similar signal requirements and similar 
temporal expression indicate that ELAG may also be 
directly involved in lymphoid cell proliferation. 
ELAG potentially encodes a nuclear phosphoprotein 
To better understand how ELAG might function during T 
cell activation and possibly in the regulation of cellular 
proliferation, I analyzed the predicted open reading frame 
to identify structural motifs. 
I have shown by in vitro translation that the 
translation of a 13.2-kDa protein is initiated from a CUG 
translational start site (Figure 16). Very few eukaryotic 
genes identified encode non-AUG start sites but the 
examples are well documented. The concept that all 
mammalian cellular proteins were translated from an AUG 
initiation codon was dispelled when Pirastu et al. showed 
that a human alpha-globin gene containing a mutated start 
codon still allowed for the production of a protein; 
although this mutation is associated with a clinical 
thalassemia (Pirastu et al., 1984). This finding 
demonstrated that the cells translational machinery could 
recognize a non-AUG translational initiation site. Since 
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then, several normal genes have been identified which 
encode proteins that initiate from non-AUG codons 
including the Drosophila encoded choline acetyltransferase 
(Sugihara et al., 1990), viral encoded genes including the 
murine leukemia virus gp85gag (Prats et al., 1989), equine 
infectious anemia virus Tat and Rev proteins (Stephens et 
al., 1990), and the parainfluenza virus C' protein (Prats 
et al., 1989). Several human genes utilize non-AUG 
translational initiation sites and include basic 
fibroblast growth factor (Prats et al., 1998; Clements et 
al., 1988), choline acetyltransferase (Strauss et al., 
1991), c-myc (Hann et al., 1992; Hann et al., 1988), int-2 
(Acland et al., 1990), TEF-1 (Xiao et al., 1991), Itk 
(Bernards and de la Monte, 1990), Hck (Lock et al., 1991), 
Krox-24 (Lemaire et al., 1990), and Trk (Martin-Zanca et 
al., 1989). 
The role of non-AUG translational initiation sites is 
unclear; however, recent investigations have shown that 
multiple isoforms of int-2 which are translated from the 
same gene are localized to different sub-cellular 
compartments (Acland et al., 1990). Additionally, Prats 
et al. suspect that the use of a non-AUG start site may be 
a post-transcriptional control mechanism {Prats et al., 
1998). 
Computer analysis predicts the presence of an amino 
acid motif beginning at position 2 (Figure 13), Pro-Arg-
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Ala-Lys-Arg, that is similar to nuclear localization 
signal (NLS) motifs identified in known nuclear factors 
(Dingwall and Laskey, 1986). This property suggests that 
ELAG is likely to function in the nucleus. 
An NLS is the minimum amino acid sequence required to 
transport protein to or retain protein in the nucleus. 
The best characterized NLS is encoded by the SV40 large T 
antigen. The minimum sequence of amino acids required for 
localization of T-antigen in the nucleus is Pro-Lys-Lys-
Lys-Arg-Lys-Val (Lanford and Butel, 1984; Kalderon et al., 
1984; Kalderon et al., 1984). Since the identification of 
this motif, similar, yet non-identical, signals have been 
identified in other proteins (Dingwall and Laskey, 1986). 
The function of the individual amino acids in the NLS is 
unclear, but they are probably important in recognition by 
chaperone proteins. 
The NLS is likely to be involved in the 
transportation of large proteins into the nucleus. 
Proteins greater than sixty kilodaltons (kDa) are excluded 
from diffusing through the nuclear pore where small 
proteins freely diffuse (Paine, 1975). However, smaller 
proteins diffuse out at the same rate in which they 
diffuse into the nucleus. Therefore, they must be 
selectively retained (Feldherr and Ogburn, 1980; Merriam 
and Hill, 1976). It is likely that the NLS serves this 
purpose for proteins smaller than 60-kDa. Since ELAG is 
only 13.2-kDa, the putative NLS may be important for 
retaining the protein in the nucleus. 
126 
Also identified in the predicted amino acid sequence 
is a Cx3Cx12Hx2H (cysteine followed by 3 amino acids, 
another cysteine followed by 12 amino acids, a histidine 
followed by 2 amino acids and a final histidine) motif 
similar to the tandemly-repeated pattern identified in the 
amino acid sequence of the Xenopus TFIIIA zinc finger 
protein (Figure 13) (Miller et al., 1985; Brown et al., 
1985). Zinc fingers are protein domains that fold 
producing an alpha helical structure which binds a zinc 
ion. 
Hundreds of genes identified encode a zinc finger-
like motif similar to the zinc finger motifs of the TFIIIA 
transcription factor (Miller et al., 1985; Brown et al., 
1985; Klevit, 1991). The function for most of these 
putative zinc finger containing proteins in many cases is 
not known. However, several proteins definitively shown 
to encode a zinc finger domain are well characterized and 
serve important regulatory functions including the 
regulation of gene expression including growth signals 
EGRl (Early Growth Response gene 1) (Sukhatme et al., 1988) 
and EGR2 (Early Growth Response gene 2) (Joseph et al., 
1988), Drosophila segmentation genes Hunchback (Tautz et 
al., 1987), and Kruppel (Rosenberg et al., 1986). In 
addition to these examples, several recently identified 
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genes involved in T cell development and activation encode 
zinc finger proteins including Ikaros (Georgopoulos et 
al., 1992) and pAT133 (Muller et al., 1991). 
Zinc finger containing proteins have been primarily 
identified as transcriptional regulators due to their 
specificity for binding target DNA in the promoter region 
of certain genes. Known transcriptional factors that 
utilize the zinc finger structure which directly interact 
with DNA include TFIID and ZIF268. These proteins 
interact with different cis elements showing that all zinc 
fingers are not alike. However, some studies show that 
the zinc finger region binding to DNA requires two 
guanosine residues with the appropriate spacing (Pavletich 
and Pabo, 1991). The finger motif binds in the large 
groove of the target DNA sequence (Pavletich and Pabo, 
1991). Most zinc finger encoding proteins contain 
multiple finger motifs, however, only a single zinc finger 
domain is required for DNA binding (Baldarelli et al., 
1988; Lee et al., 1989; Parrage et al., 1988) 
Zinc finger domains have functions other than 
transcriptional regulation through DNA binding. TFIIIA 
from Xenopus has been shown to bind to both RNA and DNA 
(Darby and Joho, 1992; Clemens et al., 1993). Recently 
Gottesfeld et al. molecularly dissected the TFIIIA 
protein, which encodes nine zinc finger domains, to 
determine which domains were essential for DNA binding and 
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those essential for RNA binding. Their results 
demonstrate that some zinc fingers were only involved in 
RNA binding while the others were involved with DNA 
binding (Clemens et al., 1993). However, they were unable 
to identify any properties such as a consensus sequence 
which would distinguish a DNA-binding zinc finger domain 
from an RNA-binding zinc finger domain. 
Other evidence suggests that zinc fingers may be 
involved in protein-protein interactions. The DNA binding 
domain of the estrogen receptor encodes two zinc finger-
like motifs; one has DNA binding capacity, the other has a 
protein interaction ability that allows it to dimerize 
with other estrogen receptor molecules (Umesoso et al., 
1991). This protein interaction which allows for the 
dimerization is essential for stable DNA binding (Umesoso 
et al., 1991). 
Computer analysis predicts that four amino acids are 
in the correct sequence context to be phosphorylated 
(Figure 13). Phosphorylation is a regulatory mechanism 
that biochemically alters a protein. Such a biochemical 
modification often functions as an on/off switch, changing 
the protein from an inert state to an active one or vice 
versa. Three amino acids Ser-48, Ser-62 and Thr-102 are 
potential substrates for phosphorylation by protein kinase 
c, a ubiquitous enzyme involved in the regulation of 
several signal transduction pathways. Ser-9 is a 
129 
potential substrate for c-raf, a proto-oncogene involved 
with a signal transduction pathway that is associated with 
cellular immortalization. 
The predicted structural properties suggest that ELAG 
may be a nuclear phosphoprotein. Further, the zinc finger 
motif would provide the capability to directly affect 
expression of other genes through protein/nucleic acid 
interactions. Direct analysis of the phosphorylation 
state of the ELAG protein may be critical in understanding 
how the protein activity is regulated. Phosphorylation/ 
dephosphorylation is an important cellular mechanism 
involved in the regulation of protein activity and 
localization (Bishop, 1987). Given the temporal 
characteristics of ELAG expression, I hypothesize that 
ELAG provides a signal to the nucleus that continues the 
cascade of T cell activation genes and initiates the 
transition from Go to G1 of the cell cycle. 
Is ELAG a novel oncogene? 
ELAG was isolated in an effort to identify novel 
oncogenes that are involved in the tumorigenic 
transformation of cells Hodgkin's disease and EBV infected 
Burkitt•s lymphoma. Two major mechanisms are involved in 
activating oncogenes (Bishop, 1987); 1) increased 
expression in oncogenes such as myc and 2) mutationally 
altered structure/function of the encoded protein like 
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Ras. To address the possibility that a mutation of ELAG 
is a transformation specific event, I was interested in 
comparing the sequence of ELAG cDNA isolated from 
activated PBMC versus the sequence of ELAG cDNA isolated 
from the L428 cell line. Only ELAG 3 type clones were 
isolated from activated PBMCs. A comparison with the 
normal clone shows that L428 derived ELAG 3 does not 
encode any mutations in the cDNA (Figure 18). Therefore, 
the potential role of ELAG 3 in transformation would only 
be due to constitutive or aberrant expression. 
During this investigation I found that ELAG is 
expressed as a family of at least four transcripts in the 
L428 Hodgkin's-disease cell line. Sequence analysis 
showed that ELAG clones 1, 2, and 3 share the same open 
reading frame that encodes a putative 13.2-kDa protein but 
have different 3 1 untranslated termini. ELAG 4 would 
encode the same amino terminus as the other 3 ELAG clones 
but because of a shortened open reading frame the entire 
protein would be only 8.2-kDa and ELAG 4 retains the 
putative NLS but would not encode the zinc finger motif. 
The role of the various transcripts and encoded proteins 
is unknown. These individual transcripts might be 
expressed in the normal counterpart of the Hodgkin's cell, 
which as of yet has not been definitively described. The 
various transcripts are potentially expressed in normal 
tissues other than activated T cells. To address this 
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possibility, we will have to study ELAG expression in an 
expanded panel of cells and tissue types. If this were 
the case one might suggest that expression of all four 
isotypes in the L428 cell is potentially a tumor specific 
event. To date, ELAG 4 has not been identified in normal 
activated PBMC. Aberrant expression of the ELAG 4 encoded 
protein may represent a tumor specific event. If this 
were the case, one might speculate that the ELAG 4 has a 
counter acting effect of a zinc finger-encoding ELAG 
protein, and that this counter activity is a critical 
deregulatory event that allows that cell to proliferate. 
Because ELAG expression is tightly regulated during T 
cell activation, it is a good candidate gene that when 
aberrantly expressed could contribute to the transformed 
phenotype of Hodgkin's disease. To test this possibility, 
ELAG expression was analyzed in several tissue culture 
lines. The data showed that ELAG is expressed at the 
greatest levels in the Hodgkin's-disease cell line L428. 
Expression was also detected in the EBV infected Burkitt•s 
lymphoma cell line Jiyoye but not in P3HR-1, the Jiyoye 
derivative. The Jiyoye cell line is infected with a fully 
transforming virus that encodes EBNA 2 (Hinuma and Grace, 
1967), a protein that is necessary for the ability of the 
virus to immortalize cells. In contrast, P3HR-1 is 
infected with a virus which does not express the EBNA 2 
gene due to a deletion in the viral genome and therefore 
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is non-transforming (Jeang and Hayward, 1983; Bornkamm et 
al., 1982). Consequently, ELAG may be expressed in 
association with a signal transduction pathway that is 
involved in Hodgkin's disease as well as transformation by 
EBV. In addition to the analysis of these cell lines, I 
showed that ELAG is not expressed at detectable levels in 
the African Burkitt•s lymphoma cell line Raji, the T cell 
lymphoma line HuT 78, the cervical carcinoma line HeLa, or 
the normal lung fibroblast line IMR-90. In addition, ELAG 
expression was not detectable in unstimulated Jurkat 
leukemic T cell line (Figure 11) or in unstimulated 
peripheral blood mononuclear cells (Figures 8, 9, 10 and 
12). These results suggest that ELAG is very tightly 
regulated in most cells but is constitutively expressed in 
the Hodgkin's-disease cell line L428 and the African 
Burkitt•s lymphoma cell line Jiyoye. This deregulated 
pattern of expression may be associated with the 
transformed phenotype of Hodgkin's disease and EBV 
transformed cells. 
Transcriptional control of ELAG 
The transcriptional control region of ELAG was 
sequenced in an effort to understand how aberrant signal 
could potentially affect ELAG expression in Hodgkin's-
disease cells and also, to investigate the molecular basis 
of the transient expression of ELAG in activated T cells. 
ELAG has a TATA-less promoter (Figure 23) which contains 
an INR that is 80% identical to the INR described in the 
murine TdT gene (Suzow and Friedman, 1993; Smale et al., 
1990). INR control elements tend to be associated with 
tightly regulated genes involved in activation, 
differentiation and development (Suzow and Friedman, 
1993). This is consistent with the tight regulation of 
ELAG that is observed in activated T cells. 
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Previous studies have shown that TATA-less genes have 
a heterogeneous transcriptional initiation site (Kozmik et 
al., 1992). Primer extension analysis showed multiple 
banding near the region that is designated as +1 (Figures 
6 and 7) indicating a heterogeneity of transcriptional 
initiation. It is likely that the TATA element found in 
most promoters is involved in ensuring that the 
transcriptional complex initiates from a single site, 
however initiation is more variable in the absence of a 
TATA element (Kozmik et al., 1992). 
One trans-acting signal that is likely to be involved 
in the transcription of ELAG is the Jun/Fos AP-1 complex. 
This complex functions by binding to the TPA response 
element (TRE) and is involved in transactivating several 
genes in response to extracellular stimulus (Holbrook and 
Fornace, 1993; Angel and Karin, 1991). PMA stimulation of 
Jurkat cells, which activates AP-1 activity, induces ELAG 
expression by four hours (Figure 11). Additionally, I 
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have identified a tandem of TREs at positions -37 and -53 
(Figure 23), providing strong evidence that the AP-1 
complex is involved in regulation of ELAG expression. Few 
early activation genes have been identified that have a 
TRE, thus ELAG may represent one of the few early 
activation genes that may be a substrate for the AP-1 
complex. Promoters containing multiple TRE elements have 
been shown to be induced to higher levels than promoters 
containing only a single element and therefore the role of 
AP-1 on ELAG expression may be very important. 
A consensus sequence for the binding of the CD28 
receptor element (CD28 RE) was identified at position -110 
from the designated transcriptional start site (Figure 
23). Recent studies have shown that CD28 is an important 
cell surface molecule that transduces a costimulatory 
signal from an antigen presenting cell that is likely to 
be required for T cell activation (Shaninian et al., 
1993). CD28 then transactivates cellular genes by 
inducing the activity of a nuclear DNA binding protein 
(Fraser et al., 1991). Genes stimulated through the CD28 
RE include IL-2 (Fraser et al., 1991), IL-3, GM-CSF, and 
interferon-gamma (Fraser and Weiss, 1992). Definitive 
evidence that stimulation of the CD28 RE will augment ELAG 
transcription would provide strong support for the notion 
that ELAG is essential for T cell activation. 
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